{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T21:14:51Z","timestamp":1794345291095,"version":"4.9.0"},"reference-count":220,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:00:00Z","timestamp":1792454400000},"content-version":"vor","delay-in-days":90,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Fundamental and Interdisciplinary Disciplines Breakthrough Plan of the Ministry of Education of China","award":["JYB2025XDXM607"],"award-info":[{"award-number":["JYB2025XDXM607"]}],"id":[{"id":"https:\/\/ror.org\/03m01yf64","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cancer"],"DOI":"10.1186\/s12943-026-02735-1","type":"journal-article","created":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:54:08Z","timestamp":1784681648000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Radiotherapy and tertiary lymphoid structures: balancing immune activation and immune damage in cancer immunotherapy"],"prefix":"10.1186","volume":"25","author":[{"given":"Yi","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongshuai","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyao","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjun","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiamin","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yating","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7042-718X","authenticated-orcid":false,"given":"Xingchen","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,22]]},"reference":[{"key":"2735_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"CA Cancer J Clin"},{"key":"2735_CR2","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/nature13954","volume":"515","author":"PC Tumeh","year":"2014","unstructured":"Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJM, Robert L, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515:568\u201371. https:\/\/doi.org\/10.1038\/nature13954.","journal-title":"Nature"},{"key":"2735_CR3","doi-asserted-by":"publisher","first-page":"eaar3593","DOI":"10.1126\/science.aar3593","volume-title":"Pan-tumor genomic biomarkers for PD-1 checkpoint blockade\u2013based immunotherapy","author":"R Cristescu","year":"2018","unstructured":"Cristescu R, Mogg R, Ayers M, Albright A, Murphy E, Yearley J, et al. Pan-tumor genomic biomarkers for PD-1 checkpoint blockade\u2013based immunotherapy. Volume 362. New York, N: Science; 2018. p. eaar3593. https:\/\/doi.org\/10.1126\/science.aar3593."},{"key":"2735_CR4","doi-asserted-by":"publisher","unstructured":"Schumacher TN, Thommen DS. Tertiary lymphoid structures in cancer. Science. New York, N.Y.; 2022;375:eabf9419. https:\/\/doi.org\/10.1126\/science.abf9419.","DOI":"10.1126\/science.abf9419"},{"key":"2735_CR5","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1038\/s41568-024-00728-0","volume":"24","author":"J-L Teillaud","year":"2024","unstructured":"Teillaud J-L, Houel A, Panouillot M, Riffard C, Dieu-Nosjean M-C. Tertiary lymphoid structures in anticancer immunity. Nat Rev Cancer. 2024;24:629\u201346. https:\/\/doi.org\/10.1038\/s41568-024-00728-0.","journal-title":"Nat Rev Cancer"},{"key":"2735_CR6","doi-asserted-by":"publisher","first-page":"1414884","DOI":"10.3389\/fimmu.2024.1414884","volume":"15","author":"B Jiang","year":"2024","unstructured":"Jiang B, Wu Z, Zhang Y, Yang X. Associations between tertiary lymphoid structure density and immune checkpoint inhibitor efficacy in solid tumors: systematic review and meta-analysis. Front Immunol. 2024;15:1414884. https:\/\/doi.org\/10.3389\/fimmu.2024.1414884.","journal-title":"Front Immunol"},{"key":"2735_CR7","doi-asserted-by":"publisher","first-page":"100546","DOI":"10.1016\/j.medj.2024.10.023","volume-title":"Tertiary lymphoid structures and cancer immunotherapy: From bench to bedside","author":"F Peyraud","year":"2025","unstructured":"Peyraud F, Guegan J-P, Vanhersecke L, Brunet M, Teyssonneau D, Palmieri L-J, et al. Tertiary lymphoid structures and cancer immunotherapy: From bench to bedside. Volume 6. New York, N: Med; 2025. p. 100546. https:\/\/doi.org\/10.1016\/j.medj.2024.10.023."},{"key":"2735_CR8","doi-asserted-by":"publisher","first-page":"10435","DOI":"10.1038\/s41467-025-65421-8","volume":"16","author":"Y Wang","year":"2025","unstructured":"Wang Y, Zhang G, Zhang X, Liu G, Zhang L, Chen L, et al. Single-cell and spatial transcriptomics implicate a prognostic function of tertiary lymphoid structures in gastric cancer. Nat Commun. 2025;16:10435. https:\/\/doi.org\/10.1038\/s41467-025-65421-8.","journal-title":"Nat Commun"},{"key":"2735_CR9","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.ccell.2022.01.002","volume":"40","author":"A Asrir","year":"2022","unstructured":"Asrir A, Tardiveau C, Coudert J, Laffont R, Blanchard L, Bellard E, et al. Tumor-associated high endothelial venules mediate lymphocyte entry into tumors and predict response to PD-1 plus CTLA-4 combination immunotherapy. Cancer Cell. 2022;40:318\u2013e3349. https:\/\/doi.org\/10.1016\/j.ccell.2022.01.002.","journal-title":"Cancer Cell"},{"key":"2735_CR10","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1038\/s41571-022-00619-z","volume":"19","author":"WH Fridman","year":"2022","unstructured":"Fridman WH, Meylan M, Petitprez F, Sun C-M, Italiano A, Saut\u00e8s-Fridman C. B cells and tertiary lymphoid structures as determinants of tumour immune contexture and clinical outcome. Nat Rev Clin Oncol. 2022;19:441\u201357. https:\/\/doi.org\/10.1038\/s41571-022-00619-z.","journal-title":"Nat Rev Clin Oncol"},{"key":"2735_CR11","doi-asserted-by":"publisher","first-page":"189500","DOI":"10.1016\/j.bbcan.2025.189500","volume":"1880","author":"J-Y Zhang","year":"2025","unstructured":"Zhang J-Y, Piao Z-Y, Su G-L, Zhang M-J, Sun Z-J. Tumor-associated high endothelial venules as therapeutic modulation targets in cancer immunotherapy. Biochim Biophys Acta BBA - Rev Cancer. 2025;1880:189500. https:\/\/doi.org\/10.1016\/j.bbcan.2025.189500.","journal-title":"Biochim Biophys Acta BBA - Rev Cancer"},{"key":"2735_CR12","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/s41586-019-1914-8","volume":"577","author":"R Cabrita","year":"2020","unstructured":"Cabrita R, Lauss M, Sanna A, Donia M, Skaarup Larsen M, Mitra S, et al. Tertiary lymphoid structures improve immunotherapy and survival in melanoma. Nature. 2020;577:561\u20135. https:\/\/doi.org\/10.1038\/s41586-019-1914-8.","journal-title":"Nature"},{"key":"2735_CR13","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1038\/s41586-019-1906-8","volume":"577","author":"F Petitprez","year":"2020","unstructured":"Petitprez F, de Reyni\u00e8s A, Keung EZ, Chen TW-W, Sun C-M, Calderaro J, et al. B cells are associated with survival and immunotherapy response in sarcoma. Nature. 2020;577:556\u201360. https:\/\/doi.org\/10.1038\/s41586-019-1906-8.","journal-title":"Nature"},{"key":"2735_CR14","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1038\/s41591-022-01821-3","volume":"28","author":"A Italiano","year":"2022","unstructured":"Italiano A, Bessede A, Pulido M, Bompas E, Piperno-Neumann S, Chevreau C, et al. Pembrolizumab in soft-tissue sarcomas with tertiary lymphoid structures: a phase 2 PEMBROSARC trial cohort. Nat Med. 2022;28:1199\u2013206. https:\/\/doi.org\/10.1038\/s41591-022-01821-3.","journal-title":"Nat Med"},{"key":"2735_CR15","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.immuni.2022.02.001","volume":"55","author":"M Meylan","year":"2022","unstructured":"Meylan M, Petitprez F, Becht E, Bougo\u00fcin A, Pupier G, Calvez A, et al. Tertiary lymphoid structures generate and propagate anti-tumor antibody-producing plasma cells in renal cell cancer. Immunity. 2022;55:527\u2013e5415. https:\/\/doi.org\/10.1016\/j.immuni.2022.02.001.","journal-title":"Immunity"},{"key":"2735_CR16","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.ccell.2022.02.002","volume":"40","author":"NS Patil","year":"2022","unstructured":"Patil NS, Nabet BY, M\u00fcller S, Koeppen H, Zou W, Giltnane J, et al. Intratumoral plasma cells predict outcomes to PD-L1 blockade in non-small cell lung cancer. Cancer Cell. 2022;40:289\u2013e3004. https:\/\/doi.org\/10.1016\/j.ccell.2022.02.002.","journal-title":"Cancer Cell"},{"key":"2735_CR17","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/s41586-019-1922-8","volume":"577","author":"BA Helmink","year":"2020","unstructured":"Helmink BA, Reddy SM, Gao J, Zhang S, Basar R, Thakur R, et al. B cells and tertiary lymphoid structures promote immunotherapy response. Nature. 2020;577:549\u201355. https:\/\/doi.org\/10.1038\/s41586-019-1922-8.","journal-title":"Nature"},{"key":"2735_CR18","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/j.immuni.2014.10.019","volume":"41","author":"L Deng","year":"2014","unstructured":"Deng L, Liang H, Xu M, Yang X, Burnette B, Arina A, et al. STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors. Immunity. 2014;41:843\u201352. https:\/\/doi.org\/10.1016\/j.immuni.2014.10.019.","journal-title":"Immunity"},{"key":"2735_CR19","doi-asserted-by":"publisher","first-page":"403","DOI":"10.18632\/oncotarget.1719","volume":"5","author":"SR Gameiro","year":"2014","unstructured":"Gameiro SR, Jammeh ML, Wattenberg MM, Tsang KY, Ferrone S, Hodge JW. Radiation-induced immunogenic modulation of tumor enhances antigen processing and calreticulin exposure, resulting in enhanced T-cell killing. Oncotarget. 2014;5:403\u201316. https:\/\/doi.org\/10.18632\/oncotarget.1719.","journal-title":"Oncotarget"},{"key":"2735_CR20","doi-asserted-by":"publisher","first-page":"15618","DOI":"10.1038\/ncomms15618","volume":"8","author":"C Vanpouille-Box","year":"2017","unstructured":"Vanpouille-Box C, Alard A, Aryankalayil MJ, Sarfraz Y, Diamond JM, Schneider RJ, et al. DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity. Nat Commun. 2017;8:15618. https:\/\/doi.org\/10.1038\/ncomms15618.","journal-title":"Nat Commun"},{"key":"2735_CR21","doi-asserted-by":"publisher","first-page":"101071","DOI":"10.1016\/j.ctro.2025.101071","volume":"56","author":"V Sandul","year":"2026","unstructured":"Sandul V, Al-Hamami SS, Kube\u0161 J, Durante M, Friedrich T. Radiation-induced lymphopenia: A data compilation to unveil relevant factors and mitigation strategies. Clin Transl Radiat Oncol. 2026;56:101071. https:\/\/doi.org\/10.1016\/j.ctro.2025.101071.","journal-title":"Clin Transl Radiat Oncol"},{"key":"2735_CR22","doi-asserted-by":"publisher","first-page":"100852","DOI":"10.1016\/j.ctro.2024.100852","volume":"49","author":"E Prades-Sagarra","year":"2024","unstructured":"Prades-Sagarra E, Yaromina A, Dubois LJ. Understanding the impact of radiation-induced lymphopenia: Preclinical and clinical research perspectives. Clin Transl Radiat Oncol. 2024;49:100852. https:\/\/doi.org\/10.1016\/j.ctro.2024.100852.","journal-title":"Clin Transl Radiat Oncol"},{"key":"2735_CR23","doi-asserted-by":"publisher","first-page":"7015","DOI":"10.1038\/s41467-022-34676-w","volume":"13","author":"LB Darragh","year":"2022","unstructured":"Darragh LB, Gadwa J, Pham TT, Van Court B, Neupert B, Olimpo NA, et al. Elective nodal irradiation mitigates local and systemic immunity generated by combination radiation and immunotherapy in head and neck tumors. Nat Commun. 2022;13:7015. https:\/\/doi.org\/10.1038\/s41467-022-34676-w.","journal-title":"Nat Commun"},{"key":"2735_CR24","doi-asserted-by":"publisher","first-page":"5500","DOI":"10.1038\/s41467-024-49873-y","volume":"15","author":"I Telarovic","year":"2024","unstructured":"Telarovic I, Yong CSM, Kurz L, Vetrugno I, Reichl S, Fernandez AS, et al. Delayed tumor-draining lymph node irradiation preserves the efficacy of combined radiotherapy and immune checkpoint blockade in models of metastatic disease. Nat Commun. 2024;15:5500. https:\/\/doi.org\/10.1038\/s41467-024-49873-y.","journal-title":"Nat Commun"},{"key":"2735_CR25","doi-asserted-by":"publisher","first-page":"104511","DOI":"10.1016\/j.mvr.2023.104511","volume":"148","author":"S Kanabuchi","year":"2023","unstructured":"Kanabuchi S, Kitamura N, Takano-Kasuya M, Inose T, Nishidate C, Yamanashi M, et al. X-ray irradiation negatively affects immune responses in the lymphatic network. Microvasc Res. 2023;148:104511. https:\/\/doi.org\/10.1016\/j.mvr.2023.104511.","journal-title":"Microvasc Res"},{"key":"2735_CR26","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s00262-025-04183-0","volume":"74","author":"C Tan","year":"2025","unstructured":"Tan C, Huang J, Gao N, Wu B, Juliet M, Xiao J, et al. Dynamic remodeling of tertiary lymphoid structures in response to cancer therapy: a recent review. Cancer Immunol Immunother. 2025;74:313. https:\/\/doi.org\/10.1007\/s00262-025-04183-0.","journal-title":"Cancer Immunol Immunother"},{"key":"2735_CR27","doi-asserted-by":"publisher","first-page":"1334408","DOI":"10.3389\/fimmu.2023.1334408","volume":"14","author":"D Wang","year":"2023","unstructured":"Wang D, Huang L, Qian D, Cao Y, Wu X, Xu P, et al. Low-dose radiotherapy promotes the formation of tertiary lymphoid structures in lung adenocarcinoma. Front Immunol. 2023;14:1334408. https:\/\/doi.org\/10.3389\/fimmu.2023.1334408.","journal-title":"Front Immunol"},{"key":"2735_CR28","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s13045-025-01754-7","volume":"18","author":"S Deng","year":"2025","unstructured":"Deng S, Chen Y, Song B, Wang H, Huang S, Wu K, et al. Tertiary lymphoid structures in cancer: spatiotemporal heterogeneity, immune orchestration, and translational opportunities. J Hematol OncolJ Hematol Oncol. 2025;18:97. https:\/\/doi.org\/10.1186\/s13045-025-01754-7.","journal-title":"J Hematol OncolJ Hematol Oncol"},{"key":"2735_CR29","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s12943-024-01980-6","volume":"23","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Xu M, Ren Y, Ba Y, Liu S, Zuo A, et al. Tertiary lymphoid structural heterogeneity determines tumour immunity and prospects for clinical application. Mol Cancer. 2024;23:75. https:\/\/doi.org\/10.1186\/s12943-024-01980-6.","journal-title":"Mol Cancer"},{"key":"2735_CR30","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1016\/j.ccell.2025.03.011","volume":"43","author":"Z Tang","year":"2025","unstructured":"Tang Z, Bai Y, Fang Q, Yuan Y, Zeng Q, Chen S, et al. Spatial transcriptomics reveals tryptophan metabolism restricting maturation of intratumoral tertiary lymphoid structures. Cancer Cell. 2025;43:1025\u2013e104414. https:\/\/doi.org\/10.1016\/j.ccell.2025.03.011.","journal-title":"Cancer Cell"},{"key":"2735_CR31","doi-asserted-by":"publisher","first-page":"101934","DOI":"10.1016\/j.xcrm.2025.101934","volume":"6","author":"F Peyraud","year":"2025","unstructured":"Peyraud F, Gu\u00e9gan J-P, Rey C, Lara O, Odin O, Del Castillo M, et al. Spatially resolved transcriptomics reveal the determinants of primary resistance to immunotherapy in NSCLC with mature tertiary lymphoid structures. Cell Rep Med. 2025;6:101934. https:\/\/doi.org\/10.1016\/j.xcrm.2025.101934.","journal-title":"Cell Rep Med"},{"key":"2735_CR32","doi-asserted-by":"publisher","first-page":"3984","DOI":"10.1158\/0008-5472.CAN-23-2716","volume":"84","author":"D An","year":"2024","unstructured":"An D, Chen G, Cheng W-Y, Mohrs K, Adler C, Gupta NT, et al. LT\u03b2R Agonism Promotes Antitumor Immune Responses via Modulation of the Tumor Microenvironment. Cancer Res. 2024;84:3984\u20134001. https:\/\/doi.org\/10.1158\/0008-5472.CAN-23-2716.","journal-title":"Cancer Res"},{"key":"2735_CR33","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1038\/s41590-025-02259-8","volume":"26","author":"J Sawada","year":"2025","unstructured":"Sawada J, Kikuchi Y, Duah M, Herrera JL, Kanamori F, Csomos K, et al. Simultaneous STING and lymphotoxin-\u03b2 receptor activation induces B cell responses in tertiary lymphoid structures to potentiate antitumor immunity. Nat Immunol. 2025;26:1766\u201380. https:\/\/doi.org\/10.1038\/s41590-025-02259-8.","journal-title":"Nat Immunol"},{"key":"2735_CR34","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/s41568-019-0144-6","volume":"19","author":"C Saut\u00e8s-Fridman","year":"2019","unstructured":"Saut\u00e8s-Fridman C, Petitprez F, Calderaro J, Fridman WH. Tertiary lymphoid structures in the era of cancer immunotherapy. Nat Rev Cancer. 2019;19:307\u201325. https:\/\/doi.org\/10.1038\/s41568-019-0144-6.","journal-title":"Nat Rev Cancer"},{"key":"2735_CR35","doi-asserted-by":"publisher","first-page":"1369626","DOI":"10.3389\/fimmu.2024.1369626","volume":"15","author":"Y Chen","year":"2024","unstructured":"Chen Y, Wu Y, Yan G, Zhang G. Tertiary lymphoid structures in cancer: maturation and induction. Front Immunol. 2024;15:1369626. https:\/\/doi.org\/10.3389\/fimmu.2024.1369626.","journal-title":"Front Immunol"},{"key":"2735_CR36","doi-asserted-by":"publisher","first-page":"1900508","DOI":"10.1080\/2162402X.2021.1900508","volume":"10","author":"NJJT Sl","year":"2021","unstructured":"Sl NJJT, Gt N. Tertiary lymphoid structures and B lymphocytes in cancer prognosis and response to immunotherapies. OncoImmunology. 2021;10:1900508. https:\/\/doi.org\/10.1080\/2162402X.2021.1900508.","journal-title":"OncoImmunology"},{"key":"2735_CR37","doi-asserted-by":"publisher","first-page":"e70046","DOI":"10.1111\/imr.70046","volume":"332","author":"J Rochefort","year":"2025","unstructured":"Rochefort J, Marodon G, Teillaud J, Dieu-Nosjean M. The Sunrise of Tertiary Lymphoid Structures in Cancer. Immunol Rev. 2025;332:e70046. https:\/\/doi.org\/10.1111\/imr.70046.","journal-title":"Immunol Rev"},{"key":"2735_CR38","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1053\/j.gastro.2023.10.022","volume":"166","author":"C Hu","year":"2024","unstructured":"Hu C, You W, Kong D, Huang Y, Lu J, Zhao M, et al. Tertiary Lymphoid Structure-Associated B Cells Enhance CXCL13\u2009+\u2009CD103+CD8\u2009+\u2009Tissue-Resident Memory T-Cell Response to Programmed Cell Death Protein 1 Blockade in Cancer Immunotherapy. Gastroenterology. 2024;166:1069\u201384. https:\/\/doi.org\/10.1053\/j.gastro.2023.10.022.","journal-title":"Gastroenterology"},{"key":"2735_CR39","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1158\/0008-5472.CAN-17-1987","volume":"78","author":"K Sili\u0146a","year":"2018","unstructured":"Sili\u0146a K, Soltermann A, Attar FM, Casanova R, Uckeley ZM, Thut H, et al. Germinal Centers Determine the Prognostic Relevance of Tertiary Lymphoid Structures and Are Impaired by Corticosteroids in Lung Squamous Cell Carcinoma. Cancer Res. 2018;78:1308\u201320. https:\/\/doi.org\/10.1158\/0008-5472.CAN-17-1987.","journal-title":"Cancer Res"},{"key":"2735_CR40","doi-asserted-by":"publisher","first-page":"101448","DOI":"10.1016\/j.xcrm.2024.101448","volume":"5","author":"W Liu","year":"2024","unstructured":"Liu W, You W, Lan Z, Ren Y, Gao S, Li S, et al. An immune cell map of human lung adenocarcinoma development reveals an anti-tumoral role of the Tfh-dependent tertiary lymphoid structure. Cell Rep Med. 2024;5:101448. https:\/\/doi.org\/10.1016\/j.xcrm.2024.101448.","journal-title":"Cell Rep Med"},{"key":"2735_CR41","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s12916-025-03889-3","volume":"23","author":"Y Xie","year":"2025","unstructured":"Xie Y, Peng H, Hu Y, Jia K, Yuan J, Liu D, et al. Immune microenvironment spatial landscapes of tertiary lymphoid structures in gastric cancer. BMC Med. 2025;23:59. https:\/\/doi.org\/10.1186\/s12916-025-03889-3.","journal-title":"BMC Med"},{"key":"2735_CR42","doi-asserted-by":"publisher","first-page":"7713","DOI":"10.1038\/s41467-024-52153-4","volume":"15","author":"Y Liu","year":"2024","unstructured":"Liu Y, Ye S-Y, He S, Chi D-M, Wang X-Z, Wen Y-F, et al. Single-cell and spatial transcriptome analyses reveal tertiary lymphoid structures linked to tumour progression and immunotherapy response in nasopharyngeal carcinoma. Nat Commun. 2024;15:7713. https:\/\/doi.org\/10.1038\/s41467-024-52153-4.","journal-title":"Nat Commun"},{"key":"2735_CR43","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1002\/mc.70058","volume":"65","author":"C Wang","year":"2026","unstructured":"Wang C, Chen W, Zhang Y, Su D, Li Y, Wei J, et al. Single-Cell and Spatial Transcriptomic Analysis Reveals Shared and Cancer\u2010Type\u2010Specific Cellular Interactions and Chemokine Signaling Associated With Tertiary Lymphoid Structures in Colorectal and Gastric Cancers. Mol Carcinog. 2026;65:153\u201366. https:\/\/doi.org\/10.1002\/mc.70058.","journal-title":"Mol Carcinog"},{"key":"2735_CR44","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1158\/0008-5472.CAN-13-1342","volume":"74","author":"J Goc","year":"2014","unstructured":"Goc J, Germain C, Vo-Bourgais TKD, Lupo A, Klein C, Knockaert S, et al. Dendritic Cells in Tumor-Associated Tertiary Lymphoid Structures Signal a Th1 Cytotoxic Immune Contexture and License the Positive Prognostic Value of Infiltrating CD8\u2009+\u2009T Cells. Cancer Res. 2014;74:705\u201315. https:\/\/doi.org\/10.1158\/0008-5472.CAN-13-1342.","journal-title":"Cancer Res"},{"key":"2735_CR45","doi-asserted-by":"publisher","first-page":"116250","DOI":"10.1016\/j.celrep.2025.116250","volume":"44","author":"X Li","year":"2025","unstructured":"Li X, Chu X, Xu W, Yang Y, Wei T, Bo Y, et al. Integrated spatial transcriptomic profiling to dissect the cellular characteristics of tumor-associated tertiary lymphoid structures. Cell Rep. 2025;44:116250. https:\/\/doi.org\/10.1016\/j.celrep.2025.116250.","journal-title":"Cell Rep"},{"key":"2735_CR46","first-page":"4228","volume":"16","author":"H Li","year":"2025","unstructured":"Li H, Zhang M-J, Zhang B, Lin W-P, Li S-J, Xiong D, et al. Mature tertiary lymphoid structures evoke intra-tumoral T and B cell responses via progenitor exhausted CD4\u2009+\u2009T cells in head and neck cancer. Nat Commun Nat Publishing Group UK Lond. 2025;16:4228.","journal-title":"Nat Commun Nat Publishing Group UK Lond"},{"key":"2735_CR47","doi-asserted-by":"publisher","first-page":"e005539","DOI":"10.1136\/jitc-2022-005539","volume":"11","author":"M He","year":"2023","unstructured":"He M, He Q, Cai X, Liu J, Deng H, Li F, et al. Intratumoral tertiary lymphoid structure (TLS) maturation is influenced by draining lymph nodes of lung cancer. J Immunother Cancer. 2023;11:e005539. https:\/\/doi.org\/10.1136\/jitc-2022-005539.","journal-title":"J Immunother Cancer"},{"key":"2735_CR48","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/j.ijrobp.2025.09.056","volume":"124","author":"N Hassan","year":"2026","unstructured":"Hassan N, Michaud E, Mansure JJ, Farag M, Kool R, Alessa M, et al. The Clinical Relevance of Tertiary Lymphoid Structures in Assessing Treatment Response in Muscle-Invasive Bladder Cancer. Int J Radiat Oncol. 2026;124:726\u201332. https:\/\/doi.org\/10.1016\/j.ijrobp.2025.09.056.","journal-title":"Int J Radiat Oncol"},{"key":"2735_CR49","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1038\/s43018-021-00232-6","volume":"2","author":"L Vanhersecke","year":"2021","unstructured":"Vanhersecke L, Brunet M, Gu\u00e9gan J-P, Rey C, Bougouin A, Cousin S, et al. Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression. Nat Cancer Nat Publishing Group US New York. 2021;2:794\u2013802. https:\/\/doi.org\/10.1038\/s43018-021-00232-6.","journal-title":"Nat Cancer Nat Publishing Group US New York"},{"key":"2735_CR50","doi-asserted-by":"publisher","first-page":"e006698","DOI":"10.1136\/jitc-2023-006698","volume":"11","author":"X Zou","year":"2023","unstructured":"Zou X, Lin X, Cheng H, Chen Y, Wang R, Ma M, et al. Characterization of intratumoral tertiary lymphoid structures in pancreatic ductal adenocarcinoma: cellular properties and prognostic significance. J Immunother Cancer. 2023;11:e006698. https:\/\/doi.org\/10.1136\/jitc-2023-006698.","journal-title":"J Immunother Cancer"},{"key":"2735_CR51","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1136\/gutjnl-2022-328697","volume":"72","author":"GS Kinker","year":"2023","unstructured":"Kinker GS, Vitiello GAF, Diniz AB, Cabral-Piccin MP, Pereira PHB, Carvalho MLR, et al. Mature tertiary lymphoid structures are key niches of tumour-specific immune responses in pancreatic ductal adenocarcinomas. Gut. 2023;72:1927\u201341. https:\/\/doi.org\/10.1136\/gutjnl-2022-328697.","journal-title":"Gut"},{"key":"2735_CR52","doi-asserted-by":"publisher","first-page":"e006425","DOI":"10.1136\/jitc-2022-006425","volume":"11","author":"C Zhang","year":"2023","unstructured":"Zhang C, Wang X-Y, Zuo J-L, Wang X-F, Feng X-W, Zhang B, et al. Localization and density of tertiary lymphoid structures associate with molecular subtype and clinical outcome in colorectal cancer liver metastases. J Immunother Cancer. 2023;11:e006425. https:\/\/doi.org\/10.1136\/jitc-2022-006425.","journal-title":"J Immunother Cancer"},{"key":"2735_CR53","doi-asserted-by":"publisher","first-page":"1166497","DOI":"10.3389\/fimmu.2023.1166497","volume":"14","author":"T Shang","year":"2023","unstructured":"Shang T, Jiang T, Lu T, Wang H, Cui X, Pan Y, et al. Tertiary lymphoid structures predict the prognosis and immunotherapy response of cholangiocarcinoma. Front Immunol. 2023;14:1166497. https:\/\/doi.org\/10.3389\/fimmu.2023.1166497.","journal-title":"Front Immunol"},{"key":"2735_CR54","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1016\/j.jhep.2021.10.030","volume":"76","author":"G-Y Ding","year":"2022","unstructured":"Ding G-Y, Ma J-Q, Yun J-P, Chen X, Ling Y, Zhang S, et al. Distribution and density of tertiary lymphoid structures predict clinical outcome in intrahepatic cholangiocarcinoma. J Hepatol. 2022;76:608\u201318. https:\/\/doi.org\/10.1016\/j.jhep.2021.10.030.","journal-title":"J Hepatol"},{"key":"2735_CR55","doi-asserted-by":"publisher","first-page":"2528","DOI":"10.1038\/s41467-024-46873-w","volume":"15","author":"L Kasikova","year":"2024","unstructured":"Kasikova L, Rakova J, Hensler M, Lanickova T, Tomankova J, Pasulka J, et al. Tertiary lymphoid structures and B cells determine clinically relevant T cell phenotypes in ovarian cancer. Nat Commun. 2024;15:2528. https:\/\/doi.org\/10.1038\/s41467-024-46873-w.","journal-title":"Nat Commun"},{"key":"2735_CR56","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1038\/s41467-022-29040-x","volume":"13","author":"N Horeweg","year":"2022","unstructured":"Horeweg N, Workel HH, Loiero D, Church DN, Vermij L, L\u00e9on-Castillo A, et al. Tertiary lymphoid structures critical for prognosis in endometrial cancer patients. Nat Commun. 2022;13:1373. https:\/\/doi.org\/10.1038\/s41467-022-29040-x.","journal-title":"Nat Commun"},{"key":"2735_CR57","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.jhep.2018.09.003","volume":"70","author":"J Calderaro","year":"2019","unstructured":"Calderaro J, Petitprez F, Becht E, Laurent A, Hirsch TZ, Rousseau B, et al. Intra-tumoral tertiary lymphoid structures are associated with a low risk of early recurrence of hepatocellular carcinoma. J Hepatol. 2019;70:58\u201365. https:\/\/doi.org\/10.1016\/j.jhep.2018.09.003.","journal-title":"J Hepatol"},{"key":"2735_CR58","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1164\/rccm.201309-1611OC","volume":"189","author":"C Germain","year":"2014","unstructured":"Germain C, Gnjatic S, Tamzalit F, Knockaert S, Remark R, Goc J, et al. Presence of B Cells in Tertiary Lymphoid Structures Is Associated with a Protective Immunity in Patients with Lung Cancer. Am J Respir Crit Care Med. 2014;189:832\u201344. https:\/\/doi.org\/10.1164\/rccm.201309-1611OC.","journal-title":"Am J Respir Crit Care Med"},{"key":"2735_CR59","doi-asserted-by":"publisher","first-page":"2466308","DOI":"10.1080\/2162402X.2025.2466308","volume":"14","author":"DA Ruiz-Torres","year":"2025","unstructured":"Ruiz-Torres DA, Bryan ME, Hirayama S, Merkin RD, Luciani E, Roberts TJ, et al. Spatial characterization of tertiary lymphoid structures as predictive biomarkers for immune checkpoint blockade in head and neck squamous cell carcinoma. OncoImmunology. 2025;14:2466308. https:\/\/doi.org\/10.1080\/2162402X.2025.2466308.","journal-title":"OncoImmunology"},{"key":"2735_CR60","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1038\/s41435-025-00346-2","volume":"26","author":"S Shen","year":"2025","unstructured":"Shen S, Sun R, Wang T, Zhang D, Che N, Wang X, et al. Impact of tertiary lymphoid structure scores and their stage of maturation on prognosis of colorectal cancer patients. Genes Immun. 2025;26:449\u201361. https:\/\/doi.org\/10.1038\/s41435-025-00346-2.","journal-title":"Genes Immun"},{"key":"2735_CR61","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1158\/0008-5472.CAN-23-3325","volume":"84","author":"G Petroni","year":"2024","unstructured":"Petroni G, Pillozzi S, Antonuzzo L. Exploiting Tertiary Lymphoid Structures to Stimulate Antitumor Immunity and Improve Immunotherapy Efficacy. Cancer Res. 2024;84:1199\u2013209. https:\/\/doi.org\/10.1158\/0008-5472.CAN-23-3325.","journal-title":"Cancer Res"},{"key":"2735_CR62","doi-asserted-by":"publisher","unstructured":"Groeneveld CS, Fontugne J, Cabel L, Bernard-Pierrot I, Radvanyi F, Allory Y et al. Tertiary lymphoid structures marker CXCL13 is associated with better survival for patients with advanced-stage bladder cancer treated with immunotherapy. Eur J Cancer. Oxford, England: 1990; 2021;148:181\u20139. https:\/\/doi.org\/10.1016\/j.ejca.2021.01.036.","DOI":"10.1016\/j.ejca.2021.01.036"},{"key":"2735_CR63","doi-asserted-by":"publisher","first-page":"1915574","DOI":"10.1080\/2162402X.2021.1915574","volume":"10","author":"L Zhou","year":"2021","unstructured":"Zhou L, Xu B, Liu Y, Wang Z. Tertiary lymphoid structure signatures are associated with survival and immunotherapy response in muscle-invasive bladder cancer. OncoImmunology. 2021;10:1915574. https:\/\/doi.org\/10.1080\/2162402X.2021.1915574.","journal-title":"OncoImmunology"},{"key":"2735_CR64","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1038\/s41590-024-01992-w","volume":"25","author":"DH Shu","year":"2024","unstructured":"Shu DH, Ho WJ, Kagohara LT, Girgis A, Shin SM, Danilova L, et al. Immunotherapy response induces divergent tertiary lymphoid structure morphologies in hepatocellular carcinoma. Nat Immunol. 2024;25:2110\u201323. https:\/\/doi.org\/10.1038\/s41590-024-01992-w.","journal-title":"Nat Immunol"},{"key":"2735_CR65","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.1016\/j.ccell.2024.09.007","volume":"42","author":"IP MacFawn","year":"2024","unstructured":"MacFawn IP, Magnon G, Gorecki G, Kunning S, Rashid R, Kaiza ME, et al. The activity of tertiary lymphoid structures in high grade serous ovarian cancer is governed by site, stroma, and cellular interactions. Cancer Cell. 2024;42:1864\u2013e18815. https:\/\/doi.org\/10.1016\/j.ccell.2024.09.007.","journal-title":"Cancer Cell"},{"key":"2735_CR66","doi-asserted-by":"publisher","first-page":"e006667","DOI":"10.1136\/jitc-2023-006667","volume":"11","author":"W Xu","year":"2023","unstructured":"Xu W, Lu J, Liu W-R, Anwaier A, Wu Y, Tian X, et al. Heterogeneity in tertiary lymphoid structures predicts distinct prognosis and immune microenvironment characterizations of clear cell renal cell carcinoma. J Immunother Cancer. 2023;11:e006667. https:\/\/doi.org\/10.1136\/jitc-2023-006667.","journal-title":"J Immunother Cancer"},{"key":"2735_CR67","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1158\/2159-8290.CD-24-0991","volume":"15","author":"MB Hugaboom","year":"2025","unstructured":"Hugaboom MB, Wirth LV, Street K, Ruthen N, Jegede OA, Schindler NR, et al. Presence of Tertiary Lymphoid Structures and Exhausted Tissue-Resident T Cells Determines Clinical Response to PD-1 Blockade in Renal Cell Carcinoma. Cancer Discov. 2025;15:948\u201368. https:\/\/doi.org\/10.1158\/2159-8290.CD-24-0991.","journal-title":"Cancer Discov"},{"key":"2735_CR68","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1158\/2326-6066.CIR-22-0110","volume":"10","author":"K Vats","year":"2022","unstructured":"Vats K, Kruglov O, Sahoo B, Soman V, Zhang J, Shurin GV, et al. Sensory Nerves Impede the Formation of Tertiary Lymphoid Structures and Development of Protective Antimelanoma Immune Responses. Cancer Immunol Res. 2022;10:1141\u201354. https:\/\/doi.org\/10.1158\/2326-6066.CIR-22-0110.","journal-title":"Cancer Immunol Res"},{"key":"2735_CR69","doi-asserted-by":"publisher","first-page":"eado8395","DOI":"10.1126\/scitranslmed.ado8395","volume":"17","author":"Z Mi","year":"2025","unstructured":"Mi Z, Chen J, Zhang Z, Liu J, Lei Y, Tan H, et al. Synthetic biology\u2013driven induction of mature TLS formation enhances antitumor immunity in colorectal cancer. Sci Transl Med. 2025;17:eado8395. https:\/\/doi.org\/10.1126\/scitranslmed.ado8395.","journal-title":"Sci Transl Med"},{"key":"2735_CR70","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.immuni.2021.12.007","volume":"55","author":"RA Chaurio","year":"2022","unstructured":"Chaurio RA, Anadon CM, Lee Costich T, Payne KK, Biswas S, Harro CM, et al. TGF-\u03b2-mediated silencing of genomic organizer SATB1 promotes Tfh cell differentiation and formation of intra-tumoral tertiary lymphoid structures. Immunity. 2022;55:115\u2013e1289. https:\/\/doi.org\/10.1016\/j.immuni.2021.12.007.","journal-title":"Immunity"},{"key":"2735_CR71","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1038\/s41586-024-08426-5","volume":"638","author":"M Amisaki","year":"2025","unstructured":"Amisaki M, Zebboudj A, Yano H, Zhang SL, Payne G, Chandra AK, et al. IL-33-activated ILC2s induce tertiary lymphoid structures in pancreatic cancer. Nature. 2025;638:1076\u201384. https:\/\/doi.org\/10.1038\/s41586-024-08426-5.","journal-title":"Nature"},{"key":"2735_CR72","doi-asserted-by":"publisher","first-page":"e002101","DOI":"10.1136\/jitc-2020-002101","volume":"9","author":"J-P Li","year":"2021","unstructured":"Li J-P, Wu C-Y, Chen M-Y, Liu S-X, Yan S-M, Kang Y-F, et al. PD-1+CXCR5\u2013CD4+ Th-CXCL13 cell subset drives B cells into tertiary lymphoid structures of nasopharyngeal carcinoma. J Immunother Cancer. 2021;9:e002101. https:\/\/doi.org\/10.1136\/jitc-2020-002101.","journal-title":"J Immunother Cancer"},{"key":"2735_CR73","doi-asserted-by":"publisher","first-page":"2280","DOI":"10.1158\/2159-8290.CD-22-0201","volume":"12","author":"A-G Goubet","year":"2022","unstructured":"Goubet A-G, Lordello L, Alves Costa Silva C, Peguillet I, Gazzano M, Mbogning-Fonkou MD, et al. Escherichia coli \u2013Specific CXCL13-Producing TFH Are Associated with Clinical Efficacy of Neoadjuvant PD-1 Blockade against Muscle-Invasive Bladder Cancer. Cancer Discov. 2022;12:2280\u2013307. https:\/\/doi.org\/10.1158\/2159-8290.CD-22-0201.","journal-title":"Cancer Discov"},{"key":"2735_CR74","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1111\/cas.70105","volume":"116","author":"M Yoshimitsu","year":"2025","unstructured":"Yoshimitsu M, Nakamura M, Kano S, Magara T, Kato H, Sakai A, et al. <scp>CXCL13<\/scp>\u2009and <scp>CCL21<\/scp> Induce Tertiary Lymphoid Structures and Enhance the Efficacy of Immunotherapy for Melanoma. Cancer Sci. 2025;116:2075\u201385. https:\/\/doi.org\/10.1111\/cas.70105.","journal-title":"Cancer Sci"},{"key":"2735_CR75","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1084\/jem.20181216","volume":"216","author":"AE Denton","year":"2019","unstructured":"Denton AE, Innocentin S, Carr EJ, Bradford BM, Lafouresse F, Mabbott NA, et al. Type I interferon induces CXCL13 to support ectopic germinal center formation. J Exp Med. 2019;216:621\u201337. https:\/\/doi.org\/10.1084\/jem.20181216.","journal-title":"J Exp Med"},{"key":"2735_CR76","doi-asserted-by":"publisher","first-page":"e2451207","DOI":"10.1002\/eji.202451207","volume":"54","author":"AL Calvanese","year":"2024","unstructured":"Calvanese AL, Cecconi V, St\u00e4heli S, Schnepf D, Nater M, Pereira P, et al. Sustained innate interferon is an essential inducer of tertiary lymphoid structures. Eur J Immunol. 2024;54:e2451207. https:\/\/doi.org\/10.1002\/eji.202451207.","journal-title":"Eur J Immunol"},{"key":"2735_CR77","doi-asserted-by":"publisher","first-page":"e13513","DOI":"10.1111\/cpr.13513","volume":"56","author":"Y Zhou","year":"2023","unstructured":"Zhou Y, Gu Q, Zhu L, Zhang S, Wu H, Pu X, et al. High endothelial venule is a prognostic immune-related biomarker in patients with resected intrahepatic cholangiocarcinoma. Cell Prolif. 2023;56:e13513. https:\/\/doi.org\/10.1111\/cpr.13513.","journal-title":"Cell Prolif"},{"key":"2735_CR78","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1158\/2326-6066.CIR-21-0369","volume":"10","author":"J Sawada","year":"2022","unstructured":"Sawada J, Hiraoka N, Qi R, Jiang L, Fournier-Goss AE, Yoshida M, et al. Molecular Signature of Tumor-Associated High Endothelial Venules That Can Predict Breast Cancer Survival. Cancer Immunol Res. 2022;10:468\u201381. https:\/\/doi.org\/10.1158\/2326-6066.CIR-21-0369.","journal-title":"Cancer Immunol Res"},{"key":"2735_CR79","doi-asserted-by":"publisher","first-page":"e003353","DOI":"10.1136\/jitc-2021-003353","volume":"9","author":"HS Park","year":"2021","unstructured":"Park HS, Kim YM, Kim S, Lee WS, Kong SJ, Yang H, et al. High endothelial venule is a surrogate biomarker for T-cell inflamed tumor microenvironment and prognosis in gastric cancer. J Immunother Cancer. 2021;9:e003353. https:\/\/doi.org\/10.1136\/jitc-2021-003353.","journal-title":"J Immunother Cancer"},{"key":"2735_CR80","doi-asserted-by":"publisher","first-page":"e191041","DOI":"10.1172\/jci.insight.191041","volume":"10","author":"W Yang","year":"2025","unstructured":"Yang W, Wu J, Cai S, Xing H, Xiang J, Zhang X, et al. VEGFD\/VEGFR2 axis induces the dedifferentiation of high endothelial venules and impairs lymphocyte homing. JCI Insight. 2025;10:e191041. https:\/\/doi.org\/10.1172\/jci.insight.191041.","journal-title":"JCI Insight"},{"key":"2735_CR81","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1158\/2767-9764.CRC-21-0123","volume":"2","author":"S Milutinovic","year":"2022","unstructured":"Milutinovic S, Abe J, Jones E, Kelch I, Smart K, Lauder SN, et al. Three-dimensional Imaging Reveals Immune-driven Tumor-associated High Endothelial Venules as a Key Correlate of Tumor Rejection Following Depletion of Regulatory T Cells. Cancer Res Commun. 2022;2:1641\u201356. https:\/\/doi.org\/10.1158\/2767-9764.CRC-21-0123.","journal-title":"Cancer Res Commun"},{"key":"2735_CR82","doi-asserted-by":"publisher","first-page":"16468","DOI":"10.1038\/s41598-023-43122-w","volume":"13","author":"D Ye","year":"2023","unstructured":"Ye D, Jin Y, Weng Y, Cui X, Wang J, Peng M, et al. High endothelial venules predict response to PD-1 inhibitors combined with anti-angiogenesis therapy in NSCLC. Sci Rep. 2023;13:16468. https:\/\/doi.org\/10.1038\/s41598-023-43122-w.","journal-title":"Sci Rep"},{"key":"2735_CR83","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1016\/j.ccell.2022.11.002","volume":"40","author":"Y Hua","year":"2022","unstructured":"Hua Y, Vella G, Rambow F, Allen E, Antoranz Martinez A, Duhamel M, et al. Cancer immunotherapies transition endothelial cells into HEVs that generate TCF1\u2009+\u2009T lymphocyte niches through a feed-forward loop. Cancer Cell. 2022;40:1600\u2013e161810. https:\/\/doi.org\/10.1016\/j.ccell.2022.11.002.","journal-title":"Cancer Cell"},{"key":"2735_CR84","doi-asserted-by":"publisher","first-page":"eaak9679","DOI":"10.1126\/scitranslmed.aak9679","volume":"9","author":"E Allen","year":"2017","unstructured":"Allen E, Jabouille A, Rivera LB, Lodewijckx I, Missiaen R, Steri V, et al. Combined antiangiogenic and anti\u2013PD-L1 therapy stimulates tumor immunity through HEV formation. Sci Transl Med. 2017;9:eaak9679. https:\/\/doi.org\/10.1126\/scitranslmed.aak9679.","journal-title":"Sci Transl Med"},{"key":"2735_CR85","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1111\/cas.15297","volume":"113","author":"J Du","year":"2022","unstructured":"Du J, Kageyama S, Yamashita R, Hirata H, Hakozaki Y, Okumura M, et al. Impacts of the STING-IFNAR1\u2010STAT1\u2010IRF1 pathway on the cellular immune reaction induced by fractionated irradiation. Cancer Sci. 2022;113:1352\u201361. https:\/\/doi.org\/10.1111\/cas.15297.","journal-title":"Cancer Sci"},{"key":"2735_CR86","doi-asserted-by":"publisher","unstructured":"Wang L, Zhou H, Chen Q, Lin Z, Jiang C, Chen X et al. STING Agonist-Loaded Nanoparticles Promotes Positive Regulation of Type I Interferon\u2010Dependent Radioimmunotherapy in Rectal Cancer. Adv Sci. Weinheim, Baden-Wurttemberg, Germany; 2024;11:e2307858. https:\/\/doi.org\/10.1002\/advs.202307858.","DOI":"10.1002\/advs.202307858"},{"key":"2735_CR87","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1186\/s12951-025-03301-5","volume":"23","author":"M Li","year":"2025","unstructured":"Li M, Lu L, Bao Q, Zhou M, Nie B, Liu Y, et al. Radiotherapy-derived engineered stem cell exosomes improve anti-glioma immunotherapy by promoting the formation of tertiary lymphoid structure and improve the release of type I interferon. J Nanobiotechnol. 2025;23:239. https:\/\/doi.org\/10.1186\/s12951-025-03301-5.","journal-title":"J Nanobiotechnol"},{"key":"2735_CR88","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1016\/j.ijrobp.2025.04.011","volume":"123","author":"Y Zheng","year":"2025","unstructured":"Zheng Y, Zhou P, Wang H, Liao S, Lin G, Kang K, et al. Stimulator of Interferon Genes Agonist Synergistically Amplifies Programmed Cell Death Protein-1 Blockade and Radiation-Induced Systemic Antitumor Responses via Tumor Microenvironment Enrichment. Int J Radiat Oncol. 2025;123:536\u201349. https:\/\/doi.org\/10.1016\/j.ijrobp.2025.04.011.","journal-title":"Int J Radiat Oncol"},{"key":"2735_CR89","doi-asserted-by":"publisher","first-page":"102200","DOI":"10.1016\/j.xcrm.2025.102200","volume":"6","author":"S-X Liu","year":"2025","unstructured":"Liu S-X, Wu T-W, Luo D-H, Zhang L-L, Zhou L, Luo Y-L, et al. Interferon-responsive HEVs drive tumor tertiary lymphoid structure formation and predict immunotherapy response in nasopharyngeal carcinoma. Cell Rep Med. 2025;6:102200. https:\/\/doi.org\/10.1016\/j.xcrm.2025.102200.","journal-title":"Cell Rep Med"},{"key":"2735_CR90","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1016\/j.ccell.2024.07.006","volume":"42","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Liu G, Zeng Q, Wu W, Lei K, Zhang C, et al. CCL19-producing fibroblasts promote tertiary lymphoid structure formation enhancing anti-tumor IgG response in colorectal cancer liver metastasis. Cancer Cell. 2024;42:1370\u2013e13859. https:\/\/doi.org\/10.1016\/j.ccell.2024.07.006.","journal-title":"Cancer Cell"},{"key":"2735_CR91","doi-asserted-by":"publisher","unstructured":"Wu S-Y, Zhang S-W, Ma D, Xiao Y, Liu Y, Chen L, et al. CCL19\u2009+\u2009dendritic cells potentiate clinical benefit of anti-PD-(L)1 immunotherapy in triple-negative breast cancer. Med. New York, N.Y. 2023; 4: 373\u2013e3938. https:\/\/doi.org\/10.1016\/j.medj.2023.04.008.","DOI":"10.1016\/j.medj.2023.04.008"},{"key":"2735_CR92","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1038\/s41419-024-07195-3","volume":"15","author":"G Fan","year":"2024","unstructured":"Fan G, Gao R, Xie T, Li L, Tang L, Han X, et al. DKK1\u2009+\u2009tumor cells inhibited the infiltration of CCL19\u2009+\u2009fibroblasts and plasma cells contributing to worse immunotherapy response in hepatocellular carcinoma. Cell Death Dis. 2024;15:797. https:\/\/doi.org\/10.1038\/s41419-024-07195-3.","journal-title":"Cell Death Dis"},{"key":"2735_CR93","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1038\/s41467-025-57465-7","volume":"16","author":"J Song","year":"2025","unstructured":"Song J, Wei R, Liu C, Zhao Z, Liu X, Wang Y, et al. Antigen-presenting cancer associated fibroblasts enhance antitumor immunity and predict immunotherapy response. Nat Commun. 2025;16:2175. https:\/\/doi.org\/10.1038\/s41467-025-57465-7.","journal-title":"Nat Commun"},{"key":"2735_CR94","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.cell.2024.10.042","volume":"188","author":"L Onder","year":"2025","unstructured":"Onder L, Papadopoulou C, L\u00fctge A, Cheng H-W, L\u00fctge M, Perez-Shibayama C, et al. Fibroblastic reticular cells generate protective intratumoral T cell environments in lung cancer. Cell. 2025;188:430\u2013e44620. https:\/\/doi.org\/10.1016\/j.cell.2024.10.042.","journal-title":"Cell"},{"key":"2735_CR95","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1016\/j.ccell.2023.04.010","volume":"41","author":"M Ramachandran","year":"2023","unstructured":"Ramachandran M, Vaccaro A, van de Walle T, Georganaki M, Lugano R, Vemuri K, et al. Tailoring vascular phenotype through AAV therapy promotes anti-tumor immunity in glioma. Cancer Cell. 2023;41:1134\u2013e115110. https:\/\/doi.org\/10.1016\/j.ccell.2023.04.010.","journal-title":"Cancer Cell"},{"key":"2735_CR96","doi-asserted-by":"publisher","first-page":"1221532","DOI":"10.3389\/fimmu.2023.1221532","volume":"14","author":"RA O\u2019Connor","year":"2023","unstructured":"O\u2019Connor RA, Martinez BR, Koppensteiner L, Mathieson L, Akram AR. Cancer-associated fibroblasts drive CXCL13 production in activated T cells via TGF-beta. Front Immunol. 2023;14:1221532. https:\/\/doi.org\/10.3389\/fimmu.2023.1221532.","journal-title":"Front Immunol"},{"key":"2735_CR97","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/j.cell.2020.07.005","volume":"182","author":"CM Sch\u00fcrch","year":"2020","unstructured":"Sch\u00fcrch CM, Bhate SS, Barlow GL, Phillips DJ, Noti L, Zlobec I, et al. Coordinated Cellular Neighborhoods Orchestrate Antitumoral Immunity at the Colorectal Cancer Invasive Front. Cell. 2020;182:1341\u2013e135919. https:\/\/doi.org\/10.1016\/j.cell.2020.07.005.","journal-title":"Cell"},{"key":"2735_CR98","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.cell.2022.12.028","volume":"186","author":"J-R Lin","year":"2023","unstructured":"Lin J-R, Wang S, Coy S, Chen Y-A, Yapp C, Tyler M, et al. Multiplexed 3D atlas of state transitions and immune interaction in colorectal cancer. Cell. 2023;186:363\u2013e38119. https:\/\/doi.org\/10.1016\/j.cell.2022.12.028.","journal-title":"Cell"},{"key":"2735_CR99","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1016\/j.cell.2018.08.039","volume":"174","author":"L Keren","year":"2018","unstructured":"Keren L, Bosse M, Marquez D, Angoshtari R, Jain S, Varma S, et al. A Structured Tumor-Immune Microenvironment in Triple Negative Breast Cancer Revealed by Multiplexed Ion Beam Imaging. Cell. 2018;174:1373\u2013e138719. https:\/\/doi.org\/10.1016\/j.cell.2018.08.039.","journal-title":"Cell"},{"key":"2735_CR100","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/j.cell.2020.05.039","volume":"182","author":"AL Ji","year":"2020","unstructured":"Ji AL, Rubin AJ, Thrane K, Jiang S, Reynolds DL, Meyers RM, et al. Multimodal Analysis of Composition and Spatial Architecture in Human Squamous Cell Carcinoma. Cell. 2020;182:497\u2013e51422. https:\/\/doi.org\/10.1016\/j.cell.2020.05.039.","journal-title":"Cell"},{"key":"2735_CR101","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1016\/j.immuni.2022.09.002","volume":"55","author":"S Liu","year":"2022","unstructured":"Liu S, Iorgulescu JB, Li S, Borji M, Barrera-Lopez IA, Shanmugam V, et al. Spatial maps of T cell receptors and transcriptomes reveal distinct immune niches and interactions in the adaptive immune response. Immunity. 2022;55:1940\u2013e19525. https:\/\/doi.org\/10.1016\/j.immuni.2022.09.002.","journal-title":"Immunity"},{"key":"2735_CR102","doi-asserted-by":"publisher","first-page":"6732","DOI":"10.1097\/JS9.0000000000001834","volume":"110","author":"Y Chen","year":"2024","unstructured":"Chen Y, Sun Z, Yin J, Ahmad MU, Zhou Z, Feng W, et al. Digital assessment of tertiary lymphoid structures and therapeutic responses in gastric cancer: a multicentric retrospective study. Int J Surg Lond Engl. 2024;110:6732\u201347. https:\/\/doi.org\/10.1097\/JS9.0000000000001834.","journal-title":"Int J Surg Lond Engl"},{"key":"2735_CR103","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1158\/1078-0432.CCR-21-2495","volume":"28","author":"BN Mills","year":"2022","unstructured":"Mills BN, Qiu H, Drage MG, Chen C, Mathew JS, Garrett-Larsen J, et al. Modulation of the Human Pancreatic Ductal Adenocarcinoma Immune Microenvironment by Stereotactic Body Radiotherapy. Clin Cancer Res. 2022;28:150\u201362. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-2495.","journal-title":"Clin Cancer Res"},{"key":"2735_CR104","doi-asserted-by":"publisher","first-page":"106030","DOI":"10.1016\/j.ebiom.2025.106030","volume":"122","author":"N Tian","year":"2025","unstructured":"Tian N, Wang Q, Lv Y, Zhong W, Li W, Cai H, et al. Mature tertiary lymphoid structures support B cell-mediated antitumour immunity and are disrupted by neoadjuvant therapy in rectal cancer: a multicentre, retrospective study. eBioMedicine. 2025;122:106030. https:\/\/doi.org\/10.1016\/j.ebiom.2025.106030.","journal-title":"eBioMedicine"},{"key":"2735_CR105","doi-asserted-by":"publisher","first-page":"930","DOI":"10.3390\/cells10040930","volume":"10","author":"RDW Vaes","year":"2021","unstructured":"Vaes RDW, Hendriks LEL, Vooijs M, De Ruysscher D. Biomarkers of Radiotherapy-Induced Immunogenic Cell Death. Cells. 2021;10:930. https:\/\/doi.org\/10.3390\/cells10040930.","journal-title":"Cells"},{"key":"2735_CR106","doi-asserted-by":"publisher","first-page":"328","DOI":"10.3109\/1547691X.2014.880533","volume":"11","author":"L Kulzer","year":"2014","unstructured":"Kulzer L, Rubner Y, Deloch L, Allg\u00e4uer A, Frey B, Fietkau R, et al. Norm- and hypo-fractionated radiotherapy is capable of activating human dendritic cells. J Immunotoxicol. 2014;11:328\u201336. https:\/\/doi.org\/10.3109\/1547691X.2014.880533.","journal-title":"J Immunotoxicol"},{"key":"2735_CR107","doi-asserted-by":"publisher","unstructured":"Gupta A, Probst HC, Vuong V, Landshammer A, Muth S, Yagita H et al. Radiotherapy Promotes Tumor-Specific Effector CD8\u2009+\u2009T Cells via Dendritic Cell Activation. J Immunol. Baltimore, Md.: 1950; 2012;189:558\u201366. https:\/\/doi.org\/10.4049\/jimmunol.1200563.","DOI":"10.4049\/jimmunol.1200563"},{"key":"2735_CR108","doi-asserted-by":"publisher","first-page":"1025872","DOI":"10.3389\/fimmu.2022.1025872","volume":"13","author":"Y Xiao","year":"2022","unstructured":"Xiao Y, Zhuang H. Effect of stereotactic radiotherapy on immune microenvironment of lung cancer. Front Immunol. 2022;13:1025872. https:\/\/doi.org\/10.3389\/fimmu.2022.1025872.","journal-title":"Front Immunol"},{"key":"2735_CR109","doi-asserted-by":"publisher","first-page":"1138920","DOI":"10.3389\/fimmu.2023.1138920","volume":"14","author":"A Eek Mariampillai","year":"2023","unstructured":"Eek Mariampillai A, Hauge S, Kongsrud K, Sylju\u00e5sen RG. Immunogenic cell death after combined treatment with radiation and ATR inhibitors is dually regulated by apoptotic caspases. Front Immunol. 2023;14:1138920. https:\/\/doi.org\/10.3389\/fimmu.2023.1138920.","journal-title":"Front Immunol"},{"key":"2735_CR110","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1084\/jem.20052494","volume":"203","author":"EA Reits","year":"2006","unstructured":"Reits EA, Hodge JW, Herberts CA, Groothuis TA, Chakraborty M, K.Wansley E, et al. Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J Exp Med. 2006;203:1259\u201371. https:\/\/doi.org\/10.1084\/jem.20052494.","journal-title":"J Exp Med"},{"key":"2735_CR111","doi-asserted-by":"publisher","unstructured":"Lugade AA, Moran JP, Gerber SA, Rose RC, Frelinger JG, Lord EM. Local Radiation Therapy of B16 Melanoma Tumors Increases the Generation of Tumor Antigen-Specific Effector Cells That Traffic to the Tumor. J Immunol. Baltimore, Md.: 1950; 2005;174:7516\u201323. https:\/\/doi.org\/10.4049\/jimmunol.174.12.7516.","DOI":"10.4049\/jimmunol.174.12.7516"},{"key":"2735_CR112","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1111\/imm.13592","volume":"168","author":"X Zhang","year":"2023","unstructured":"Zhang X, Zhang H, Zhang J, Yang M, Zhu M, Yin Y, et al. The paradoxical role of radiation-induced\u2009<\u2009scp>cGAS\u2013STING signalling network in tumour immunity. Immunology. 2023;168:375\u201388. https:\/\/doi.org\/10.1111\/imm.13592.","journal-title":"Immunology"},{"key":"2735_CR113","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.1080\/09553002.2023.2232011","volume":"99","author":"Y He","year":"2023","unstructured":"He Y, Yang Y, Huang W, Yang S, Xue X, Zhu K, et al. Manganese facilitated cGAS-STING-IFNI pathway activation induced by ionizing radiation in glioma cells. Int J Radiat Biol. 2023;99:1890\u2013907. https:\/\/doi.org\/10.1080\/09553002.2023.2232011.","journal-title":"Int J Radiat Biol"},{"key":"2735_CR114","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1158\/2326-6066.CIR-15-0253","volume":"4","author":"SJ Dovedi","year":"2016","unstructured":"Dovedi SJ, Lipowska-Bhalla G, Beers SA, Cheadle EJ, Mu L, Glennie MJ, et al. Antitumor Efficacy of Radiation plus Immunotherapy Depends upon Dendritic Cell Activation of Effector CD8\u2009+\u2009T Cells. Cancer Immunol Res. 2016;4:621\u201330. https:\/\/doi.org\/10.1158\/2326-6066.CIR-15-0253.","journal-title":"Cancer Immunol Res"},{"key":"2735_CR115","doi-asserted-by":"publisher","first-page":"e6950","DOI":"10.1002\/cam4.6950","volume":"13","author":"W Hu","year":"2024","unstructured":"Hu W, Zhang Z, Xue Y, Ning R, Guo X, Sun Y, et al. Carbon ion irradiation exerts antitumor activity by inducing\u2009<\u2009scp>cGAS\u2013STING activation and immune response in prostate cancer-bearing mice. Cancer Med. 2024;13:e6950. https:\/\/doi.org\/10.1002\/cam4.6950.","journal-title":"Cancer Med"},{"key":"2735_CR116","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1016\/j.ijrobp.2021.12.162","volume":"112","author":"S-S Du","year":"2022","unstructured":"Du S-S, Chen G-W, Yang P, Chen Y-X, Hu Y, Zhao Q-Q, et al. Radiation Therapy Promotes Hepatocellular Carcinoma Immune Cloaking via PD-L1 Upregulation Induced by cGAS-STING Activation. Int J Radiat Oncol. 2022;112:1243\u201355. https:\/\/doi.org\/10.1016\/j.ijrobp.2021.12.162.","journal-title":"Int J Radiat Oncol"},{"key":"2735_CR117","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/nature14292","volume":"520","author":"C Twyman-Saint Victor","year":"2015","unstructured":"Twyman-Saint Victor C, Rech AJ, Maity A, Rengan R, Pauken KE, Stelekati E, et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature. 2015;520:373\u20137. https:\/\/doi.org\/10.1038\/nature14292.","journal-title":"Nature"},{"key":"2735_CR118","doi-asserted-by":"publisher","first-page":"5458","DOI":"10.1158\/0008-5472.CAN-14-1258","volume":"74","author":"SJ Dovedi","year":"2014","unstructured":"Dovedi SJ, Adlard AL, Lipowska-Bhalla G, McKenna C, Jones S, Cheadle EJ, et al. Acquired Resistance to Fractionated Radiotherapy Can Be Overcome by Concurrent PD-L1 Blockade. Cancer Res. 2014;74:5458\u201368. https:\/\/doi.org\/10.1158\/0008-5472.CAN-14-1258.","journal-title":"Cancer Res"},{"key":"2735_CR119","doi-asserted-by":"crossref","unstructured":"Zhang T, Yu H, Ni C, Zhang T, Liu L, Lv Q et al. Hypofractionated stereotactic radiation therapy activates the peripheral immune response in operable stage I non-small-cell lung cancer. Sci Rep. Nature Publishing Group UK London; 2017;7:4866.","DOI":"10.1038\/s41598-017-04978-x"},{"key":"2735_CR120","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1111\/1759-7714.13122","volume":"10","author":"NA Lockney","year":"2019","unstructured":"Lockney NA, Zhang M, Morris CG, Nichols RC, Okunieff P, Swarts S, et al. Radiation-induced tumor immunity in patients with non\u2010small cell lung cancer. Thorac Cancer. 2019;10:1605\u201311. https:\/\/doi.org\/10.1111\/1759-7714.13122.","journal-title":"Thorac Cancer"},{"key":"2735_CR121","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/bs.ircmb.2023.03.002","volume":"378","author":"F de Kermenguy","year":"2023","unstructured":"de Kermenguy F, Meziani L, Mondini M, Cl\u00e9menson C, Morel D, Deutsch E, et al. Radio-induced lymphopenia in the era of anti-cancer immunotherapy. Int Rev Cell Mol Biol. 2023;378:1\u201330. https:\/\/doi.org\/10.1016\/bs.ircmb.2023.03.002.","journal-title":"Int Rev Cell Mol Biol"},{"key":"2735_CR122","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.ijrobp.2018.09.010","volume":"103","author":"LRG Pike","year":"2019","unstructured":"Pike LRG, Bang A, Mahal BA, Taylor A, Krishnan M, Spektor A, et al. The Impact of Radiation Therapy on Lymphocyte Count and Survival in Metastatic Cancer Patients Receiving PD-1 Immune Checkpoint Inhibitors. Int J Radiat Oncol. 2019;103:142\u201351. https:\/\/doi.org\/10.1016\/j.ijrobp.2018.09.010.","journal-title":"Int J Radiat Oncol"},{"key":"2735_CR123","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/j.ijrobp.2025.09.042","volume":"124","author":"C Bo","year":"2026","unstructured":"Bo C, Lv Z, Zhang H, Hou X, Wang Y, Liu J, et al. Proton Therapy May Reduce the Risk of Cancer Progression During Immune Checkpoint Inhibitor Therapy: A Propensity Score-Matched Analysis of Intensity Modulated Proton Versus Photon Radiation Therapy. Int J Radiat Oncol. 2026;124:733\u201344. https:\/\/doi.org\/10.1016\/j.ijrobp.2025.09.042.","journal-title":"Int J Radiat Oncol"},{"key":"2735_CR124","doi-asserted-by":"publisher","first-page":"23","DOI":"10.14338\/IJPT-17-00033.1","volume":"4","author":"P Fang","year":"2017","unstructured":"Fang P, Shiraishi Y, Verma V, Jiang W, Song J, Hobbs BP, et al. Lymphocyte-Sparing Effect of Proton Therapy in Patients with Esophageal Cancer Treated with Definitive Chemoradiation. Int J Part Ther. 2017;4:23\u201332. https:\/\/doi.org\/10.14338\/IJPT-17-00033.1.","journal-title":"Int J Part Ther"},{"key":"2735_CR125","doi-asserted-by":"publisher","first-page":"140","DOI":"10.3109\/07357907.2012.762780","volume":"31","author":"S Yovino","year":"2013","unstructured":"Yovino S, Kleinberg L, Grossman SA, Narayanan M, Ford E. The Etiology of Treatment-related Lymphopenia in Patients with Malignant Gliomas: Modeling Radiation Dose to Circulating Lymphocytes Explains Clinical Observations and Suggests Methods of Modifying the Impact of Radiation on Immune Cells. Cancer Invest. 2013;31:140\u20134. https:\/\/doi.org\/10.3109\/07357907.2012.762780.","journal-title":"Cancer Invest"},{"key":"2735_CR126","doi-asserted-by":"publisher","unstructured":"Jin J-Y, Mereniuk T, Yalamanchali A, Wang W, Machtay M, (Spring)Kong F-M, et al. A framework for modeling radiation induced lymphopenia in radiotherapy. Radiother Oncol. 2020;144:105\u201313. https:\/\/doi.org\/10.1016\/j.radonc.2019.11.014.","DOI":"10.1016\/j.radonc.2019.11.014"},{"key":"2735_CR127","doi-asserted-by":"publisher","first-page":"149","DOI":"10.2217\/cns.12.14","volume":"1","author":"S Yovino","year":"2012","unstructured":"Yovino S, Grossman SA. Severity, etiology and possible consequences of treatment-related lymphopenia in patients with newly diagnosed high-grade gliomas. CNS Oncol. 2012;1:149\u201354. https:\/\/doi.org\/10.2217\/cns.12.14.","journal-title":"CNS Oncol"},{"key":"2735_CR128","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.ijrobp.2015.11.026","volume":"94","author":"AT Wild","year":"2016","unstructured":"Wild AT, Herman JM, Dholakia AS, Moningi S, Lu Y, Rosati LM, et al. Lymphocyte-Sparing Effect of Stereotactic Body Radiation Therapy in Patients With Unresectable Pancreatic Cancer. Int J Radiat Oncol. 2016;94:571\u20139. https:\/\/doi.org\/10.1016\/j.ijrobp.2015.11.026.","journal-title":"Int J Radiat Oncol"},{"key":"2735_CR129","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1016\/j.jtho.2020.06.008","volume":"15","author":"A Abravan","year":"2020","unstructured":"Abravan A, Faivre-Finn C, Kennedy J, McWilliam A, van Herk M. Radiotherapy-Related Lymphopenia Affects Overall Survival in Patients With Lung Cancer. J Thorac Oncol. 2020;15:1624\u201335. https:\/\/doi.org\/10.1016\/j.jtho.2020.06.008.","journal-title":"J Thorac Oncol"},{"key":"2735_CR130","doi-asserted-by":"publisher","first-page":"eabn6758","DOI":"10.1126\/scitranslmed.abn6758","volume":"15","author":"S Ghosh","year":"2023","unstructured":"Ghosh S, Huang J, Inkman M, Zhang J, Thotala S, Tikhonova E, et al. Radiation-induced circulating myeloid-derived suppressor cells induce systemic lymphopenia after chemoradiotherapy in patients with glioblastoma. Sci Transl Med. 2023;15:eabn6758. https:\/\/doi.org\/10.1126\/scitranslmed.abn6758.","journal-title":"Sci Transl Med"},{"key":"2735_CR131","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.ijrobp.2023.11.037","volume":"119","author":"J Ma","year":"2024","unstructured":"Ma J, Li Y, Yu H, Zhang J, Zhang Y, Verma V, et al. The Role of Thoracic Vertebral Body Dosimetry in Minimizing Acute Hematologic Toxicities of Patients With Non-Small Cell Lung Cancer Receiving Lung Radiation Therapy and Immunotherapy. Int J Radiat Oncol. 2024;119:78\u201389. https:\/\/doi.org\/10.1016\/j.ijrobp.2023.11.037.","journal-title":"Int J Radiat Oncol"},{"key":"2735_CR132","doi-asserted-by":"publisher","first-page":"100391","DOI":"10.1016\/j.jtocrr.2022.100391","volume":"3","author":"W Jing","year":"2022","unstructured":"Jing W, Xu T, Wu L, Lopez PB, Grassberger C, Ellsworth SG, et al. Severe Radiation-Induced Lymphopenia Attenuates the Benefit of Durvalumab After Concurrent Chemoradiotherapy for NSCLC. JTO Clin Res Rep. 2022;3:100391. https:\/\/doi.org\/10.1016\/j.jtocrr.2022.100391.","journal-title":"JTO Clin Res Rep"},{"key":"2735_CR133","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1093\/jrr\/rrac084","volume":"64","author":"M Nakamura","year":"2023","unstructured":"Nakamura M, Ishikawa H, Ohnishi K, Mori Y, Baba K, Nakazawa K, et al. Effects of lymphopenia on survival in proton therapy with chemotherapy for non-small cell lung cancer. J Radiat Res (Tokyo). 2023;64:438\u201347. https:\/\/doi.org\/10.1093\/jrr\/rrac084.","journal-title":"J Radiat Res (Tokyo)"},{"key":"2735_CR134","doi-asserted-by":"publisher","first-page":"vdae088","DOI":"10.1093\/noajnl\/vdae088","volume":"6","author":"A Das","year":"2024","unstructured":"Das A, Sylvia J, Krishnan G, Panda PK, Subramanyam P, Kumar R, et al. Impact of intensity-modulated proton therapy in reducing radiation-induced lymphopenia in glioma patients. Neuro-Oncol Adv. 2024;6:vdae088. https:\/\/doi.org\/10.1093\/noajnl\/vdae088.","journal-title":"Neuro-Oncol Adv"},{"key":"2735_CR135","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1093\/jrr\/rrae023","volume":"65","author":"Y Ma","year":"2024","unstructured":"Ma Y, Kong Y, Zhang S, Peng Y, Xu M, Zhang J, et al. The relationship between splenic dose and radiation-induced lymphopenia. J Radiat Res (Tokyo). 2024;65:337\u201349. https:\/\/doi.org\/10.1093\/jrr\/rrae023.","journal-title":"J Radiat Res (Tokyo)"},{"key":"2735_CR136","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.ijrobp.2024.12.014","volume":"122","author":"PJJ Damen","year":"2025","unstructured":"Damen PJJ, Peters M, Hobbs B, Chen Y, Titt U, Nout R, et al. Defining the Optimal Radiation-induced Lymphopenia Metric to Discern Its Survival Impact in Esophageal Cancer. Int J Radiat Oncol. 2025;122:31\u201342. https:\/\/doi.org\/10.1016\/j.ijrobp.2024.12.014.","journal-title":"Int J Radiat Oncol"},{"key":"2735_CR137","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.ijrobp.2021.04.009","volume":"111","author":"E Reijmen","year":"2021","unstructured":"Reijmen E, De Mey S, De Mey W, Gevaert T, De Ridder K, Locy H, et al. Fractionated Radiation Severely Reduces the Number of CD8\u2009+\u2009T Cells and Mature Antigen Presenting Cells Within Lung Tumors. Int J Radiat Oncol. 2021;111:272\u201383. https:\/\/doi.org\/10.1016\/j.ijrobp.2021.04.009.","journal-title":"Int J Radiat Oncol"},{"key":"2735_CR138","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1158\/2326-6066.CIR-17-0040","volume":"5","author":"Y Muroyama","year":"2017","unstructured":"Muroyama Y, Nirschl TR, Kochel CM, Lopez-Bujanda Z, Theodros D, Mao W, et al. Stereotactic Radiotherapy Increases Functionally Suppressive Regulatory T Cells in the Tumor Microenvironment. Cancer Immunol Res. 2017;5:992\u20131004. https:\/\/doi.org\/10.1158\/2326-6066.CIR-17-0040.","journal-title":"Cancer Immunol Res"},{"key":"2735_CR139","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1158\/2326-6066.CIR-21-1105","volume":"10","author":"C Jim\u00e9nez-Cortegana","year":"2022","unstructured":"Jim\u00e9nez-Cortegana C, Galassi C, Klapp V, Gabrilovich DI, Galluzzi L. Myeloid-Derived Suppressor Cells and Radiotherapy. Cancer Immunol Res. 2022;10:545\u201357. https:\/\/doi.org\/10.1158\/2326-6066.CIR-21-1105.","journal-title":"Cancer Immunol Res"},{"key":"2735_CR140","doi-asserted-by":"publisher","first-page":"e20250641","DOI":"10.1084\/jem.20250641","volume":"223","author":"D Chen","year":"2026","unstructured":"Chen D, Wang L, Wen C, Piffko A, Bugno J, Yu X, et al. Radiotherapy induces YTHDF2 in dendritic cells impairing cross-presentation and T cell function. J Exp Med. 2026;223:e20250641. https:\/\/doi.org\/10.1084\/jem.20250641.","journal-title":"J Exp Med"},{"key":"2735_CR141","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.ccr.2013.09.014","volume":"24","author":"F Klug","year":"2013","unstructured":"Klug F, Prakash H, Huber PE, Seibel T, Bender N, Halama N, et al. Low-Dose Irradiation Programs Macrophage Differentiation to an iNOS+\/M1 Phenotype that Orchestrates Effective T Cell Immunotherapy. Cancer Cell. 2013;24:589\u2013602. https:\/\/doi.org\/10.1016\/j.ccr.2013.09.014.","journal-title":"Cancer Cell"},{"key":"2735_CR142","doi-asserted-by":"publisher","first-page":"5379","DOI":"10.1158\/1078-0432.CCR-09-0265","volume":"15","author":"MZ Dewan","year":"2009","unstructured":"Dewan MZ, Galloway AE, Kawashima N, Dewyngaert JK, Babb JS, Formenti SC, et al. Fractionated but Not Single-Dose Radiotherapy Induces an Immune-Mediated Abscopal Effect when Combined with Anti\u2013CTLA-4 Antibody. Clin Cancer Res. 2009;15:5379\u201388. https:\/\/doi.org\/10.1158\/1078-0432.CCR-09-0265.","journal-title":"Clin Cancer Res"},{"key":"2735_CR143","doi-asserted-by":"publisher","first-page":"e002038","DOI":"10.1136\/jitc-2020-002038","volume":"9","author":"S Demaria","year":"2021","unstructured":"Demaria S, Guha C, Schoenfeld J, Morris Z, Monjazeb A, Sikora A, et al. Radiation dose and fraction in immunotherapy: one-size regimen does not fit all settings, so how does one choose? J Immunother Cancer. 2021;9:e002038. https:\/\/doi.org\/10.1136\/jitc-2020-002038.","journal-title":"J Immunother Cancer"},{"key":"2735_CR144","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1002\/cac2.12348","volume":"42","author":"Z Liu","year":"2022","unstructured":"Liu Z, Yu Z, Chen D, Verma V, Yuan C, Wang M, et al. Pivotal roles of tumor-draining lymph nodes in the abscopal effects from combined immunotherapy and radiotherapy. Cancer Commun Lond Engl. 2022;42:971\u201386. https:\/\/doi.org\/10.1002\/cac2.12348.","journal-title":"Cancer Commun Lond Engl"},{"key":"2735_CR145","doi-asserted-by":"publisher","first-page":"3522","DOI":"10.1038\/s41467-025-58510-1","volume":"16","author":"Y Shen","year":"2025","unstructured":"Shen Y, Connolly E, Aiello M, Zhou C, Chappa P, Song H, et al. Combination radiation and \u03b1PD-L1 enhance tumor control by stimulating CD8\u2009+\u2009PD-1\u2009+\u2009TCF-1\u2009+\u2009T cells in the tumor-draining lymph node. Nat Commun. 2025;16:3522. https:\/\/doi.org\/10.1038\/s41467-025-58510-1.","journal-title":"Nat Commun"},{"key":"2735_CR146","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/j.ccell.2020.09.001","volume":"38","author":"F Dammeijer","year":"2020","unstructured":"Dammeijer F, van Gulijk M, Mulder EE, Lukkes M, Klaase L, van den Bosch T, et al. The PD-1\/PD-L1-Checkpoint Restrains T cell Immunity in Tumor-Draining Lymph Nodes. Cancer Cell. 2020;38:685\u2013e7008. https:\/\/doi.org\/10.1016\/j.ccell.2020.09.001.","journal-title":"Cancer Cell"},{"key":"2735_CR147","doi-asserted-by":"publisher","unstructured":"Reichl S, Pruschy M, Kreuzer M, Balermpas P, Telarovic I. Translating spared and delayed tumor-draining lymph node irradiation into clinical practice: Current clinical trials and future directions. Eur J Cancer. Oxford, England: 1990; 2025;226:115601. https:\/\/doi.org\/10.1016\/j.ejca.2025.115601.","DOI":"10.1016\/j.ejca.2025.115601"},{"key":"2735_CR148","doi-asserted-by":"publisher","first-page":"uxaf040","DOI":"10.1093\/cei\/uxaf040","volume":"219","author":"JM Heather","year":"2025","unstructured":"Heather JM, Kim DW, Sepulveda SM, van Seventer EE, Fish MG, Corcoran R, et al. The differential immunological impact of photon vs proton radiation therapy in high-grade lymphopenia in patients with gastrointestinal tumors. Clin Exp Immunol. 2025;219:uxaf040. https:\/\/doi.org\/10.1093\/cei\/uxaf040.","journal-title":"Clin Exp Immunol"},{"key":"2735_CR149","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/j.ijrobp.2020.09.053","volume":"109","author":"CS Spina","year":"2021","unstructured":"Spina CS, Tsuruoka C, Mao W, Sunaoshi MM, Chaimowitz M, Shang Y, et al. Differential Immune Modulation With Carbon-Ion Versus Photon Therapy. Int J Radiat Oncol. 2021;109:813\u20138. https:\/\/doi.org\/10.1016\/j.ijrobp.2020.09.053.","journal-title":"Int J Radiat Oncol"},{"key":"2735_CR150","doi-asserted-by":"publisher","first-page":"13444","DOI":"10.1038\/s41598-021-92942-1","volume":"11","author":"C Mirjolet","year":"2021","unstructured":"Mirjolet C, Nicol A, Limagne E, Mura C, Richard C, Morgand V, et al. Impact of proton therapy on antitumor immune response. Sci Rep. 2021;11:13444. https:\/\/doi.org\/10.1038\/s41598-021-92942-1.","journal-title":"Sci Rep"},{"key":"2735_CR151","doi-asserted-by":"publisher","first-page":"217895","DOI":"10.1016\/j.canlet.2025.217895","volume":"630","author":"Y Guo","year":"2025","unstructured":"Guo Y, Hao S, Huang Q, Di C, Gan L, Xie Y, et al. Unraveling the dual nature of FLASH radiotherapy: From normal tissue sparing to tumor control. Cancer Lett. 2025;630:217895. https:\/\/doi.org\/10.1016\/j.canlet.2025.217895.","journal-title":"Cancer Lett"},{"key":"2735_CR152","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1016\/j.ijrobp.2022.05.038","volume":"114","author":"TT B\u00f6hlen","year":"2022","unstructured":"B\u00f6hlen TT, Germond J-F, Bourhis J, Vozenin M-C, Ozsahin EM, Bochud F, et al. Normal Tissue Sparing by FLASH as a Function of Single-Fraction Dose: A Quantitative Analysis. Int J Radiat Oncol. 2022;114:1032\u201344. https:\/\/doi.org\/10.1016\/j.ijrobp.2022.05.038.","journal-title":"Int J Radiat Oncol"},{"key":"2735_CR153","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.ijrobp.2020.05.002","volume":"108","author":"L Yin","year":"2020","unstructured":"Yin L, Xue J, Li R, Zhou L, Deng L, Chen L, et al. Effect of Low-Dose Radiation Therapy on Abscopal Responses to Hypofractionated Radiation Therapy and Anti-PD1 in Mice and Patients With Non-Small Cell Lung Cancer. Int J Radiat Oncol. 2020;108:212\u201324. https:\/\/doi.org\/10.1016\/j.ijrobp.2020.05.002.","journal-title":"Int J Radiat Oncol"},{"key":"2735_CR154","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1016\/j.ijrobp.2021.03.047","volume":"110","author":"C Moore","year":"2021","unstructured":"Moore C, Hsu C-C, Chen W-M, Chen BPC, Han C, Story M, et al. Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy (PULSAR) in Preclinical Models Enhances Single-Agent Immune Checkpoint Blockade. Int J Radiat Oncol. 2021;110:1306\u201316. https:\/\/doi.org\/10.1016\/j.ijrobp.2021.03.047.","journal-title":"Int J Radiat Oncol"},{"key":"2735_CR155","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1186\/s40425-019-0634-9","volume":"7","author":"M Grapin","year":"2019","unstructured":"Grapin M, Richard C, Limagne E, Boidot R, Morgand V, Bertaut A, et al. Optimized fractionated radiotherapy with anti-PD-L1 and anti-TIGIT: a promising new combination. J Immunother Cancer. 2019;7:160. https:\/\/doi.org\/10.1186\/s40425-019-0634-9.","journal-title":"J Immunother Cancer"},{"key":"2735_CR156","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1093\/jnci\/djae329","volume":"117","author":"A Buqu\u00e9","year":"2025","unstructured":"Buqu\u00e9 A, Bloy N, Petroni G, Jim\u00e9nez-Cortegana C, Sato A, Iribarren C, et al. Impact of radiation therapy dose, fractionation, and immunotherapeutic partner in a mouse model of hormone receptor\u2013positive mammary carcinogenesis. JNCI J Natl Cancer Inst. 2025;117:934\u201347. https:\/\/doi.org\/10.1093\/jnci\/djae329.","journal-title":"JNCI J Natl Cancer Inst"},{"key":"2735_CR157","doi-asserted-by":"publisher","first-page":"188704","DOI":"10.1016\/j.bbcan.2022.188704","volume":"1877","author":"MI Koukourakis","year":"2022","unstructured":"Koukourakis MI, Giatromanolaki A. Tumor draining lymph nodes, immune response, and radiotherapy: Towards a revisal of therapeutic principles. Biochim Biophys Acta BBA - Rev Cancer. 2022;1877:188704. https:\/\/doi.org\/10.1016\/j.bbcan.2022.188704.","journal-title":"Biochim Biophys Acta BBA - Rev Cancer"},{"key":"2735_CR158","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/j.trecan.2025.04.008","volume":"11","author":"J von Renesse","year":"2025","unstructured":"von Renesse J, Lin M-C, Ho P-C. Tumor-draining lymph nodes \u2013 friend or foe during immune checkpoint therapy? Trends Cancer. 2025;11:676\u201390. https:\/\/doi.org\/10.1016\/j.trecan.2025.04.008.","journal-title":"Trends Cancer"},{"key":"2735_CR159","doi-asserted-by":"publisher","first-page":"e124507","DOI":"10.1172\/jci.insight.124507","volume":"3","author":"MF Fransen","year":"2018","unstructured":"Fransen MF, Schoonderwoerd M, Knopf P, Camps MG, Hawinkels LJ, Kneilling M, et al. Tumor-draining lymph nodes are pivotal in PD-1\/PD-L1 checkpoint therapy. JCI Insight. 2018;3:e124507. https:\/\/doi.org\/10.1172\/jci.insight.124507.","journal-title":"JCI Insight"},{"key":"2735_CR160","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1158\/1078-0432.CCR-24-4123","volume":"31","author":"I Tseng","year":"2025","unstructured":"Tseng I, Chen Y, Ai D, Zhu Z, Zhao W, Fan M, et al. Radiation Dose\u2013Volume Effects on Negative Tumor-Draining Lymph Nodes Affected T-cell Activation and Prognosis in Esophageal Cancer with Chemoradiotherapy. Clin Cancer Res. 2025;31:2024\u201333. https:\/\/doi.org\/10.1158\/1078-0432.CCR-24-4123.","journal-title":"Clin Cancer Res"},{"key":"2735_CR161","doi-asserted-by":"publisher","first-page":"100812","DOI":"10.1016\/j.neo.2022.100812","volume-title":"Radiation-induced lymphopenia does not impact treatment efficacy in a mouse tumor model","author":"I Telarovic","year":"2022","unstructured":"Telarovic I, Yong CSM, Guckenberger M, Unkelbach J, Pruschy M. Radiation-induced lymphopenia does not impact treatment efficacy in a mouse tumor model. Volume 31. New York, N: Neoplasia; 2022. p. 100812. https:\/\/doi.org\/10.1016\/j.neo.2022.100812."},{"key":"2735_CR162","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s13014-024-02514-6","volume":"19","author":"RA Bekker","year":"2024","unstructured":"Bekker RA, Obertopp N, Redler G, Penagaricano J, Caudell JJ, Yamoah K, et al. Spatially fractionated GRID radiation potentiates immune-mediated tumor control. Radiat Oncol Lond Engl. 2024;19:121. https:\/\/doi.org\/10.1186\/s13014-024-02514-6.","journal-title":"Radiat Oncol Lond Engl"},{"key":"2735_CR163","doi-asserted-by":"publisher","first-page":"3","DOI":"10.14338\/IJPT-20-00070.1","volume":"8","author":"L Wang","year":"2021","unstructured":"Wang L, Fossati P, Paganetti H, Ma L, Gillison M, Myers JN, et al. The Biological Basis for Enhanced Effects of Proton Radiation Therapy Relative to Photon Radiation Therapy for Head and Neck Squamous Cell Carcinoma. Int J Part Ther. 2021;8:3\u201313. https:\/\/doi.org\/10.14338\/IJPT-20-00070.1.","journal-title":"Int J Part Ther"},{"key":"2735_CR164","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1007\/s00066-024-02263-1","volume":"200","author":"P Loap","year":"2024","unstructured":"Loap P, Vu-Bezin J, De Marzi L, Kirova Y. Proton therapy reduces the effective dose to immune cells in breast cancer patients. Strahlenther Onkol. 2024;200:1074\u20139. https:\/\/doi.org\/10.1007\/s00066-024-02263-1.","journal-title":"Strahlenther Onkol"},{"key":"2735_CR165","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.ijrobp.2021.08.015","volume":"112","author":"H Paganetti","year":"2022","unstructured":"Paganetti H. Mechanisms and Review of Clinical Evidence of Variations in Relative Biological Effectiveness in Proton Therapy. Int J Radiat Oncol. 2022;112:222\u201336. https:\/\/doi.org\/10.1016\/j.ijrobp.2021.08.015.","journal-title":"Int J Radiat Oncol"},{"key":"2735_CR166","doi-asserted-by":"publisher","first-page":"2057892","DOI":"10.1080\/2162402X.2022.2057892","volume":"11","author":"H Zhou","year":"2022","unstructured":"Zhou H, Tu C, Yang P, Li J, Kepp O, Li H, et al. Carbon ion radiotherapy triggers immunogenic cell death and sensitizes melanoma to anti-PD-1 therapy in mice. OncoImmunology. 2022;11:2057892. https:\/\/doi.org\/10.1080\/2162402X.2022.2057892.","journal-title":"OncoImmunology"},{"key":"2735_CR167","doi-asserted-by":"publisher","first-page":"215928","DOI":"10.1016\/j.canlet.2022.215928","volume":"550","author":"L Hartmann","year":"2022","unstructured":"Hartmann L, Osen W, Eichm\u00fcller OL, Korda\u00df T, Furkel J, Dickes E, et al. Carbon ion irradiation plus CTLA4 blockade elicits therapeutic immune responses in a murine tumor model. Cancer Lett. 2022;550:215928. https:\/\/doi.org\/10.1016\/j.canlet.2022.215928.","journal-title":"Cancer Lett"},{"key":"2735_CR168","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1186\/s12967-025-06377-7","volume":"23","author":"H Burckel","year":"2025","unstructured":"Burckel H, Nicol A, Mura C, Rousseau M, Bou-Gharios J, Froidurot L, et al. Distinct immune responses to proton and photon radiotherapy: implications for anti-PD-L1 combination therapy in colorectal cancer. J Transl Med. 2025;23:360. https:\/\/doi.org\/10.1186\/s12967-025-06377-7.","journal-title":"J Transl Med"},{"key":"2735_CR169","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-026-04724-z","author":"G Furini","year":"2026","unstructured":"Furini G, Mota da Silva E, Usai A, Scabia G, Kusmic C, Faita F, et al. FLASH radiotherapy preserves systemic and tissue homeostasis while maintaining antitumor efficacy. BMC Med [Internet]. 2026. https:\/\/doi.org\/10.1186\/s12916-026-04724-z.","journal-title":"BMC Med [Internet]"},{"key":"2735_CR170","doi-asserted-by":"publisher","unstructured":"Saenz FR, Velasquez B, Waldrop T, Aguilar E, Cox KR, Delahoussaye A et al. FLASH radiotherapy spares lymphocytes in tumor-draining lymph nodes and increases infiltration of immune cells in tumors. bioRxiv; 2025. https:\/\/doi.org\/10.1101\/2025.04.07.647544.\u00a0 Cited 2026 Mar 4.","DOI":"10.1101\/2025.04.07.647544"},{"key":"2735_CR171","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.radonc.2017.05.003","volume":"124","author":"P Montay-Gruel","year":"2017","unstructured":"Montay-Gruel P, Petersson K, Jaccard M, Boivin G, Germond J-F, Petit B, et al. Irradiation in a flash: Unique sparing of memory in mice after whole brain irradiation with dose rates above 100 Gy\/s. Radiother Oncol. 2017;124:365\u20139. https:\/\/doi.org\/10.1016\/j.radonc.2017.05.003.","journal-title":"Radiother Oncol"},{"key":"2735_CR172","doi-asserted-by":"publisher","first-page":"245ra93","DOI":"10.1126\/scitranslmed.3008973","volume":"6","author":"V Favaudon","year":"2014","unstructured":"Favaudon V, Caplier L, Monceau V, Pouzoulet F, Sayarath M, Fouillade C, et al. Ultrahigh dose-rate FLASH irradiation increases the differential response between normal and tumor tissue in mice. Sci Transl Med. 2014;6:245ra93. https:\/\/doi.org\/10.1126\/scitranslmed.3008973.","journal-title":"Sci Transl Med"},{"key":"2735_CR173","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.radonc.2020.04.054","volume":"149","author":"J-Y Jin","year":"2020","unstructured":"Jin J-Y, Gu A, Wang W, Oleinick NL, Machtay M. (Spring) Kong F-M. Ultra-high dose rate effect on circulating immune cells: A potential mechanism for FLASH effect? Radiother Oncol. 2020;149:55\u201362. https:\/\/doi.org\/10.1016\/j.radonc.2020.04.054.","journal-title":"Radiother Oncol"},{"key":"2735_CR174","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.ijrobp.2019.10.049","volume":"106","author":"ES Diffenderfer","year":"2020","unstructured":"Diffenderfer ES, Verginadis II, Kim MM, Shoniyozov K, Velalopoulou A, Goia D, et al. Design, Implementation, and in Vivo Validation of a Novel Proton FLASH Radiation Therapy System. Int J Radiat Oncol. 2020;106:440\u20138. https:\/\/doi.org\/10.1016\/j.ijrobp.2019.10.049.","journal-title":"Int J Radiat Oncol"},{"key":"2735_CR175","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.ijrobp.2022.12.018","volume":"116","author":"L Iturri","year":"2023","unstructured":"Iturri L, Bertho A, Lamirault C, Juchaux M, Gilbert C, Espenon J, et al. Proton FLASH Radiation Therapy and Immune Infiltration: Evaluation in an Orthotopic Glioma Rat Model. Int J Radiat Oncol. 2023;116:655\u201365. https:\/\/doi.org\/10.1016\/j.ijrobp.2022.12.018.","journal-title":"Int J Radiat Oncol"},{"key":"2735_CR176","doi-asserted-by":"publisher","first-page":"109741","DOI":"10.1016\/j.radonc.2023.109741","volume":"186","author":"S Shukla","year":"2023","unstructured":"Shukla S, Saha T, Rama N, Acharya A, Le T, Bian F, et al. Ultra-high dose-rate proton FLASH improves tumor control. Radiother Oncol. 2023;186:109741. https:\/\/doi.org\/10.1016\/j.radonc.2023.109741.","journal-title":"Radiother Oncol"},{"key":"2735_CR177","doi-asserted-by":"publisher","first-page":"4099","DOI":"10.1002\/mp.15623","volume":"49","author":"PA Taylor","year":"2022","unstructured":"Taylor PA, Moran JM, Jaffray DA, Buchsbaum JC. A roadmap to clinical trials for FLASH. Med Phys. 2022;49:4099\u2013108. https:\/\/doi.org\/10.1002\/mp.15623.","journal-title":"Med Phys"},{"key":"2735_CR178","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1001\/jamaoncol.2022.5843","volume":"9","author":"AE Mascia","year":"2023","unstructured":"Mascia AE, Daugherty EC, Zhang Y, Lee E, Xiao Z, Sertorio M, et al. Proton FLASH Radiotherapy for the Treatment of Symptomatic Bone Metastases. JAMA Oncol. 2023;9:62. https:\/\/doi.org\/10.1001\/jamaoncol.2022.5843.","journal-title":"JAMA Oncol"},{"key":"2735_CR179","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s13045-018-0647-8","volume":"11","author":"Y Liu","year":"2018","unstructured":"Liu Y, Dong Y, Kong L, Shi F, Zhu H, Yu J. Abscopal effect of radiotherapy combined with immune checkpoint inhibitors. J Hematol OncolJ Hematol Oncol. 2018;11:104. https:\/\/doi.org\/10.1186\/s13045-018-0647-8.","journal-title":"J Hematol OncolJ Hematol Oncol"},{"key":"2735_CR180","doi-asserted-by":"publisher","first-page":"e70346","DOI":"10.1002\/mco2.70346","volume":"6","author":"X Wang","year":"2025","unstructured":"Wang X, Jing J. Cancer Immunotherapy in Combination with Radiotherapy and\/or Chemotherapy: Mechanisms and Clinical Therapy. MedComm. 2025;6:e70346. https:\/\/doi.org\/10.1002\/mco2.70346.","journal-title":"MedComm"},{"key":"2735_CR181","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/S1470-2045(15)00054-6","volume":"16","author":"EB Golden","year":"2015","unstructured":"Golden EB, Chhabra A, Chachoua A, Adams S, Donach M, Fenton-Kerimian M, et al. Local radiotherapy and granulocyte-macrophage colony-stimulating factor to generate abscopal responses in patients with metastatic solid tumours: a proof-of-principle trial. Lancet Oncol. 2015;16:795\u2013803. https:\/\/doi.org\/10.1016\/S1470-2045(15)00054-6.","journal-title":"Lancet Oncol"},{"key":"2735_CR182","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1038\/s41591-018-0232-2","volume":"24","author":"SC Formenti","year":"2018","unstructured":"Formenti SC, Rudqvist N-P, Golden E, Cooper B, Wennerberg E, Lhuillier C, et al. Radiotherapy induces responses of lung cancer to CTLA-4 blockade. Nat Med. 2018;24:1845\u201351. https:\/\/doi.org\/10.1038\/s41591-018-0232-2.","journal-title":"Nat Med"},{"key":"2735_CR183","doi-asserted-by":"publisher","first-page":"11061","DOI":"10.3390\/ijms222011061","volume":"22","author":"JR Janopaul-Naylor","year":"2021","unstructured":"Janopaul-Naylor JR, Shen Y, Qian DC, Buchwald ZS. The Abscopal Effect: A Review of Pre-Clinical and Clinical Advances. Int J Mol Sci. 2021;22:11061. https:\/\/doi.org\/10.3390\/ijms222011061.","journal-title":"Int J Mol Sci"},{"key":"2735_CR184","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.currproblcancer.2015.10.001","volume":"40","author":"Y Abuodeh","year":"2016","unstructured":"Abuodeh Y, Venkat P, Kim S. Systematic review of case reports on the abscopal effect. Curr Probl Cancer. 2016;40:25\u201337. https:\/\/doi.org\/10.1016\/j.currproblcancer.2015.10.001.","journal-title":"Curr Probl Cancer"},{"key":"2735_CR185","doi-asserted-by":"publisher","first-page":"299","DOI":"10.2217\/imt-2017-0082","volume":"10","author":"ML Aliru","year":"2018","unstructured":"Aliru ML, Schoenhals JE, Venkatesulu BP, Anderson CC, Barsoumian HB, Younes AI, et al. Radiation Therapy and Immunotherapy: What is the Optimal Timing or Sequencing? Immunotherapy. 2018;10:299\u2013316. https:\/\/doi.org\/10.2217\/imt-2017-0082.","journal-title":"Immunotherapy"},{"key":"2735_CR186","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.ctro.2017.12.004","volume":"9","author":"R Chicas-Sett","year":"2018","unstructured":"Chicas-Sett R, Morales-Orue I, Rodriguez-Abreu D, Lara-Jimenez P. Combining radiotherapy and ipilimumab induces clinically relevant radiation-induced abscopal effects in metastatic melanoma patients: A systematic review. Clin Transl Radiat Oncol. 2018;9:5\u201311. https:\/\/doi.org\/10.1016\/j.ctro.2017.12.004.","journal-title":"Clin Transl Radiat Oncol"},{"key":"2735_CR187","doi-asserted-by":"publisher","first-page":"e000732","DOI":"10.1136\/bmjonc-2025-000732","volume":"4","author":"E Urias","year":"2025","unstructured":"Urias E, Lee J, Weil CR, Roach E, Lloyd S, Hashibe M, et al. Combined immune checkpoint inhibitors and ablative radiotherapy in metastatic cancers: a meta-analysis of prospective clinical trials. BMJ Oncol. 2025;4:e000732. https:\/\/doi.org\/10.1136\/bmjonc-2025-000732.","journal-title":"BMJ Oncol"},{"key":"2735_CR188","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1158\/1535-7163.MCT-14-1015","volume":"14","author":"M Mondini","year":"2015","unstructured":"Mondini M, Nizard M, Tran T, Mauge L, Loi M, Cl\u00e9menson C, et al. Synergy of radiotherapy and a cancer vaccine for the treatment of HPV-associated head and neck cancer. Mol Cancer Ther Am Association Cancer Res. 2015;14:1336\u201345. https:\/\/doi.org\/10.1158\/1535-7163.MCT-14-1015.","journal-title":"Mol Cancer Ther Am Association Cancer Res"},{"key":"2735_CR189","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/S2213-2600(20)30391-X","volume":"9","author":"WSME Theelen","year":"2021","unstructured":"Theelen WSME, Chen D, Verma V, Hobbs BP, Peulen HMU, Aerts JGJV, et al. Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Respir Med. 2021;9:467\u201375. https:\/\/doi.org\/10.1016\/S2213-2600(20)30391-X.","journal-title":"Lancet Respir Med"},{"key":"2735_CR190","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/S1470-2045(21)00658-6","volume":"23","author":"JD Schoenfeld","year":"2022","unstructured":"Schoenfeld JD, Giobbie-Hurder A, Ranasinghe S, Kao KZ, Lako A, Tsuji J, et al. Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial. Lancet Oncol. 2022;23:279\u201391. https:\/\/doi.org\/10.1016\/S1470-2045(21)00658-6.","journal-title":"Lancet Oncol"},{"key":"2735_CR191","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1200\/JCO.2017.76.2229","volume":"36","author":"JJ Luke","year":"2018","unstructured":"Luke JJ, Lemons JM, Karrison TG, Pitroda SP, Melotek JM, Zha Y, et al. Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors. J Clin Oncol. 2018;36:1611\u20138. https:\/\/doi.org\/10.1200\/JCO.2017.76.2229.","journal-title":"J Clin Oncol"},{"key":"2735_CR192","doi-asserted-by":"publisher","first-page":"e002485","DOI":"10.1136\/jitc-2021-002485","volume":"9","author":"R Leidner","year":"2021","unstructured":"Leidner R, Crittenden M, Young K, Xiao H, Wu Y, Couey MA, et al. Neoadjuvant immunoradiotherapy results in high rate of complete pathological response and clinical to pathological downstaging in locally advanced head and neck squamous cell carcinoma. J Immunother Cancer. 2021;9:e002485. https:\/\/doi.org\/10.1136\/jitc-2021-002485.","journal-title":"J Immunother Cancer"},{"key":"2735_CR193","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1038\/s41590-025-02219-2","volume":"26","author":"SKM Wijesinghe","year":"2025","unstructured":"Wijesinghe SKM, Rausch L, Gabriel SS, Galletti G, De Luca M, Qin L, et al. Lymph-node-derived stem-like but not tumor-tissue-resident CD8\u2009+\u2009T cells fuel anticancer immunity. Nat Immunol. 2025;26:1367\u201383. https:\/\/doi.org\/10.1038\/s41590-025-02219-2.","journal-title":"Nat Immunol"},{"key":"2735_CR194","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1016\/j.immuni.2021.08.026","volume":"54","author":"JM Schenkel","year":"2021","unstructured":"Schenkel JM, Herbst RH, Canner D, Li A, Hillman M, Shanahan S-L, et al. Conventional type I dendritic cells maintain a reservoir of proliferative tumor-antigen specific TCF-1\u2009+\u2009CD8+ T cells in tumor-draining lymph nodes. Immunity. 2021;54:2338\u2013e23536. https:\/\/doi.org\/10.1016\/j.immuni.2021.08.026.","journal-title":"Immunity"},{"key":"2735_CR195","doi-asserted-by":"publisher","first-page":"4049","DOI":"10.1016\/j.cell.2022.09.020","volume":"185","author":"Q Huang","year":"2022","unstructured":"Huang Q, Wu X, Wang Z, Chen X, Wang L, Lu Y, et al. The primordial differentiation of tumor-specific memory CD8\u2009+\u2009T cells as bona fide responders to PD-1\/PD-L1 blockade in draining lymph nodes. Cell. 2022;185:4049\u2013e406625. https:\/\/doi.org\/10.1016\/j.cell.2022.09.020.","journal-title":"Cell"},{"key":"2735_CR196","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1007\/s00262-025-04187-w","volume":"74","author":"J Zhang","year":"2025","unstructured":"Zhang J, Ma J, Niu Y, Liu J, Wang Z, Guo J, et al. Tumor-draining lymph nodes respond to immune checkpoint inhibition and orchestrate tumor immune remodeling. Cancer Immunol Immunother. 2025;74:326. https:\/\/doi.org\/10.1007\/s00262-025-04187-w.","journal-title":"Cancer Immunol Immunother"},{"key":"2735_CR197","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1007\/s00262-020-02792-5","volume":"70","author":"MJ O\u2019Melia","year":"2021","unstructured":"O\u2019Melia MJ, Manspeaker MP, Thomas SN. Tumor-draining lymph nodes are survival niches that support T cell priming against lymphatic transported tumor antigen and effects of immune checkpoint blockade in TNBC. Cancer Immunol Immunother. 2021;70:2179\u201395. https:\/\/doi.org\/10.1007\/s00262-020-02792-5.","journal-title":"Cancer Immunol Immunother"},{"key":"2735_CR198","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1038\/s43018-022-00338-5","volume":"3","author":"M Cohen","year":"2022","unstructured":"Cohen M, Giladi A, Barboy O, Hamon P, Li B, Zada M, et al. The interaction of CD4\u2009+\u2009helper T cells with dendritic cells shapes the tumor microenvironment and immune checkpoint blockade response. Nat Cancer. 2022;3:303\u201317. https:\/\/doi.org\/10.1038\/s43018-022-00338-5.","journal-title":"Nat Cancer"},{"key":"2735_CR199","doi-asserted-by":"publisher","first-page":"e013237","DOI":"10.1136\/jitc-2025-013237","volume":"13","author":"EB Ulas","year":"2025","unstructured":"Ulas EB, Koomen SJI, Vrijmoet A, Houda I, Korkmaz HI, Dickhoff C, et al. Immune-modulating effects on tumor-draining lymph nodes of neoadjuvant chemoradiotherapy combined with dual immunotherapy in patients with T3-4N0-2 NSCLC. J Immunother Cancer. 2025;13:e013237. https:\/\/doi.org\/10.1136\/jitc-2025-013237.","journal-title":"J Immunother Cancer"},{"key":"2735_CR200","doi-asserted-by":"publisher","first-page":"6578","DOI":"10.1038\/s41467-025-61780-4","volume":"16","author":"R Saddawi-Konefka","year":"2025","unstructured":"Saddawi-Konefka R, Msari RA, Tang S, Philips C, Sadat S, Clubb LM, et al. The tumor-sentinel lymph node immuno-migratome reveals CCR7+ dendritic cells drive response to sequenced immunoradiotherapy. Nat Commun. 2025;16:6578. https:\/\/doi.org\/10.1038\/s41467-025-61780-4.","journal-title":"Nat Commun"},{"key":"2735_CR201","doi-asserted-by":"publisher","unstructured":"Weiss JM, Subleski JJ, Back T, Chen X, Watkins SK, Yagita H et al. Regulatory T Cells and Myeloid-Derived Suppressor Cells in the Tumor Microenvironment Undergo Fas-Dependent Cell Death during IL-2\/\u03b1CD40 Therapy. J Immunol. Baltimore, Md.: 1950; 2014;192:5821\u20139. https:\/\/doi.org\/10.4049\/jimmunol.1400404.","DOI":"10.4049\/jimmunol.1400404"},{"key":"2735_CR202","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.ccell.2014.10.006","volume":"26","author":"RK Jain","year":"2014","unstructured":"Jain RK. Antiangiogenesis Strategies Revisited: From Starving Tumors to Alleviating Hypoxia. Cancer Cell. 2014;26:605\u201322. https:\/\/doi.org\/10.1016\/j.ccell.2014.10.006.","journal-title":"Cancer Cell"},{"key":"2735_CR203","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.1158\/1078-0432.CCR-14-2742","volume":"21","author":"H-M Chen","year":"2015","unstructured":"Chen H-M, Ma G, Gildener-Leapman N, Eisenstein S, Coakley BA, Ozao J, et al. Myeloid-Derived Suppressor Cells as an Immune Parameter in Patients with Concurrent Sunitinib and Stereotactic Body Radiotherapy. Clin Cancer Res. 2015;21:4073\u201385. https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-2742.","journal-title":"Clin Cancer Res"},{"key":"2735_CR204","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/S0140-6736(23)01384-3","volume":"402","author":"JY Chang","year":"2023","unstructured":"Chang JY, Lin SH, Dong W, Liao Z, Gandhi SJ, Gay CM, et al. Stereotactic ablative radiotherapy with or without immunotherapy for early-stage or isolated lung parenchymal recurrent node-negative non-small-cell lung cancer: an open-label, randomised, phase 2 trial. Lancet Lond Engl. 2023;402:871\u201381. https:\/\/doi.org\/10.1016\/S0140-6736(23)01384-3.","journal-title":"Lancet Lond Engl"},{"key":"2735_CR205","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","volume":"377","author":"SJ Antonia","year":"2017","unstructured":"Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Durvalumab after Chemoradiotherapy in Stage III Non\u2013Small-Cell Lung Cancer. N Engl J Med. 2017;377:1919\u201329. https:\/\/doi.org\/10.1056\/NEJMoa1709937.","journal-title":"N Engl J Med"},{"key":"2735_CR206","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/S1470-2045(21)00149-2","volume":"22","author":"NK Altorki","year":"2021","unstructured":"Altorki NK, McGraw TE, Borczuk AC, Saxena A, Port JL, Stiles BM, et al. Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: a single-centre, randomised phase 2 trial. Lancet Oncol. 2021;22:824\u201335. https:\/\/doi.org\/10.1016\/S1470-2045(21)00149-2.","journal-title":"Lancet Oncol"},{"key":"2735_CR207","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/S1470-2045(24)00100-1","volume":"25","author":"J-P Machiels","year":"2024","unstructured":"Machiels J-P, Tao Y, Licitra L, Burtness B, Tahara M, Rischin D, et al. Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2024;25:572\u201387. https:\/\/doi.org\/10.1016\/S1470-2045(24)00100-1.","journal-title":"Lancet Oncol"},{"key":"2735_CR208","doi-asserted-by":"publisher","unstructured":"Lorusso D, Xiang Y, Hasegawa K, Scambia G, Leiva M, Ramos-Elias P et al. Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11\/GOG-3047\/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial. The Lancet. London, England; 2024;403:1341\u201350. https:\/\/doi.org\/10.1016\/S0140-6736(24)00317-9.","DOI":"10.1016\/S0140-6736(24)00317-9"},{"key":"2735_CR209","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1056\/NEJMoa2404873","volume":"391","author":"Y Cheng","year":"2024","unstructured":"Cheng Y, Spigel DR, Cho BC, Laktionov KK, Fang J, Chen Y, et al. Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer. N Engl J Med. 2024;391:1313\u201327. https:\/\/doi.org\/10.1056\/NEJMoa2404873.","journal-title":"N Engl J Med"},{"key":"2735_CR210","doi-asserted-by":"publisher","first-page":"3610","DOI":"10.1200\/JCO-25-00036","volume":"43","author":"JD Bradley","year":"2025","unstructured":"Bradley JD, Sugawara S, Lee KH, Ostoros G, Demirkazik A, Zemanova M, et al. Simultaneous Durvalumab and Platinum-Based Chemoradiotherapy in Unresectable Stage III Non\u2013Small Cell Lung Cancer: The Phase III PACIFIC-2 Study. J Clin Oncol. 2025;43:3610\u201321. https:\/\/doi.org\/10.1200\/JCO-25-00036.","journal-title":"J Clin Oncol"},{"key":"2735_CR211","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1038\/s41586-022-05672-3","volume":"614","author":"M Sorin","year":"2023","unstructured":"Sorin M, Rezanejad M, Karimi E, Fiset B, Desharnais L, Perus LJM, et al. Single-cell spatial landscapes of the lung tumour immune microenvironment. Nature. 2023;614:548\u201354. https:\/\/doi.org\/10.1038\/s41586-022-05672-3.","journal-title":"Nature"},{"key":"2735_CR212","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.ccell.2023.12.012","volume":"42","author":"SL Shiao","year":"2024","unstructured":"Shiao SL, Gouin KH, Ing N, Ho A, Basho R, Shah A, et al. Single-cell and spatial profiling identify three response trajectories to pembrolizumab and radiation therapy in triple negative breast cancer. Cancer Cell. 2024;42:70\u2013e848. https:\/\/doi.org\/10.1016\/j.ccell.2023.12.012.","journal-title":"Cancer Cell"},{"key":"2735_CR213","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.ccell.2022.05.009","volume":"40","author":"VM Ravi","year":"2022","unstructured":"Ravi VM, Will P, Kueckelhaus J, Sun N, Joseph K, Sali\u00e9 H, et al. Spatially resolved multi-omics deciphers bidirectional tumor-host interdependence in glioblastoma. Cancer Cell. 2022;40:639\u2013e65513. https:\/\/doi.org\/10.1016\/j.ccell.2022.05.009.","journal-title":"Cancer Cell"},{"key":"2735_CR214","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1038\/s41586-022-05680-3","volume":"614","author":"E Karimi","year":"2023","unstructured":"Karimi E, Yu MW, Maritan SM, Perus LJM, Rezanejad M, Sorin M, et al. Single-cell spatial immune landscapes of primary and metastatic brain tumours. Nature. 2023;614:555\u201363. https:\/\/doi.org\/10.1038\/s41586-022-05680-3.","journal-title":"Nature"},{"key":"2735_CR215","doi-asserted-by":"publisher","first-page":"e009879","DOI":"10.1136\/jitc-2024-009879","volume":"12","author":"S Long","year":"2024","unstructured":"Long S, Li M, Chen J, Zhong L, Abudulimu A, Zhou L, et al. Spatial patterns and MRI-based radiomic prediction of high peritumoral tertiary lymphoid structure density in hepatocellular carcinoma: a multicenter study. J Immunother Cancer. 2024;12:e009879. https:\/\/doi.org\/10.1136\/jitc-2024-009879.","journal-title":"J Immunother Cancer"},{"key":"2735_CR216","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/j.ccell.2025.01.014","volume":"43","author":"C Xu","year":"2025","unstructured":"Xu C, Zhou G-Q, Li W-F, Hu D-S, Chen X-Z, Lin S-J, et al. Nivolumab combined with induction chemotherapy and radiotherapy in nasopharyngeal carcinoma: A multicenter phase 2 PLATINUM trial. Cancer Cell. 2025;43:925\u2013e9364. https:\/\/doi.org\/10.1016\/j.ccell.2025.01.014.","journal-title":"Cancer Cell"},{"key":"2735_CR217","doi-asserted-by":"publisher","first-page":"3351","DOI":"10.1158\/1078-0432.CCR-20-4443","volume":"27","author":"T van den Ende","year":"2021","unstructured":"van den Ende T, de Clercq NC, van Berge Henegouwen MI, Gisbertz SS, Geijsen ED, Verhoeven RHA, et al. Neoadjuvant Chemoradiotherapy Combined with Atezolizumab for Resectable Esophageal Adenocarcinoma: A Single-arm Phase II Feasibility Trial (PERFECT). Clin Cancer Res. 2021;27:3351\u20139. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-4443.","journal-title":"Clin Cancer Res"},{"key":"2735_CR218","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.annonc.2022.10.006","volume":"34","author":"Y Tao","year":"2023","unstructured":"Tao Y, Biau J, Sun XS, Sire C, Martin L, Alfonsi M, et al. Pembrolizumab versus cetuximab concurrent with radiotherapy in patients with locally advanced squamous cell carcinoma of head and neck unfit for cisplatin (GORTEC 2015-01 PembroRad): a multicenter, randomized, phase II trial. Ann Oncol. 2023;34:101\u201310. https:\/\/doi.org\/10.1016\/j.annonc.2022.10.006.","journal-title":"Ann Oncol"},{"key":"2735_CR219","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1016\/S0140-6736(22)01659-2","volume":"400","author":"S Kim","year":"2022","unstructured":"Kim S, Wuthrick E, Blakaj D, Eroglu Z, Verschraegen C, Thapa R, et al. Combined nivolumab and ipilimumab with or without stereotactic body radiation therapy for advanced Merkel cell carcinoma: a randomised, open label, phase 2 trial. Lancet Lond Engl. 2022;400:1008\u201319. https:\/\/doi.org\/10.1016\/S0140-6736(22)01659-2.","journal-title":"Lancet Lond Engl"},{"key":"2735_CR220","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1038\/s43018-025-01018-w","volume":"6","author":"J Huang","year":"2025","unstructured":"Huang J, Theelen WSME, Belcaid Z, Najjar M, van der Geest D, Singh D, et al. Combination of pembrolizumab and radiotherapy induces systemic antitumor immune responses in immunologically cold non-small cell lung cancer. Nat Cancer. 2025;6:1676\u201392. https:\/\/doi.org\/10.1038\/s43018-025-01018-w.","journal-title":"Nat Cancer"}],"container-title":["Molecular Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12943-026-02735-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-026-02735-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-026-02735-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:58:25Z","timestamp":1792457905000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12943-026-02735-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,22]]},"references-count":220,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2735"],"URL":"https:\/\/doi.org\/10.1186\/s12943-026-02735-1","relation":{},"ISSN":["1476-4598"],"issn-type":[{"value":"1476-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,22]]},"assertion":[{"value":"15 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"245"}}